伊洛前列素对博来霉素诱导小鼠肺纤维化的干预作用及相关机制研究
摘要
目的:建立博来霉素诱导小鼠肺纤维化模型,观察伊洛前列素对肺纤维的可能干预作用;并进一步探讨可能的机制。
方法:
1.应用单次气管内注入博来霉素(2mg/kg体重)的方法复制小鼠肺纤维化模型,并通过单次腹腔内注射伊洛前列素(200ug/kg体重)来实现对小鼠肺纤维化的干预。
2.观测小鼠体重变化,生存指数,肺组织羟脯氨酸测定,病理切片Ashcroft评分及肺泡间隔厚度测定评估小鼠肺纤维化的严重程度,采用Flexivent系统评价博来霉素诱导肺纤维化小鼠肺功能改变,并评价伊洛前列素的干预作用。
3.通过半定量RT-PCR测定肺组织中细胞因子和趋化因子mRNA的表达水平,评价伊洛前列素对细胞因子表达的影响。
4.应用ELISA试剂盒测定BALF中细胞因子和趋化因子在蛋白水平的表达,评价伊洛前列素对细胞因子表达的影响。
结果:
1.伊洛前列素组小鼠与博来霉素组相比,在如下方面存在显著性差异:气管内注药后第6至第18天平均体重(p＜0.05),生存指数(90%vs 40%,p＜0.01),肺组织羟脯氨酸测定(56.04±2.23 ug/ml vs 77±6.01ug/ml,p＜0.05),肺纤维化Ashcroft评分(3.35±0.54 vs 5.64±0.18,p＜0.01),肺泡间隔厚度测定(23.03±4.91 vs 56.12±4.06,p＜0.01),小鼠肺组织弹性(49.96 cmH20/ml±1.83 vs 86.84±13.13cmH20/ml,p＜0.01),肺组织顺应性(0.02015±0.00074 ml/cmH20 vs 0.01448±0.00178ml/cmH20,p＜0.05),均显示伊洛前列素治疗组优于博来霉素组。
2.伊洛前列素组与博来霉素组相比,可显著降低以下细胞因子mRNA表达水平:IL-6(0.75±0.33 vs 1.67±0.22,p＜0.05),TNF-α(0.28±0.02 vs0.44±0.05,p＜0.05),TGF-β(0.90±0.10 vs 1.26±0.07,p＜0.05);并可显著提高以下细胞因子表达水平:IFN-γ(0.90±0.10 vs 1.26±0.07,p＜0.05),CXCL10(1.03±0.09 vs 0.76±0.03,p＜0.05),CXCL11(0.35±0.04 vs 0.22±0.02,p＜0.05)。
3.在蛋白水平伊洛前列素可影响BALF中以下细胞因子的表达:降低IL-6(26.5±4.04 pg/ml vs 131.5±38.21pg/ml,p＜0.05)和TGF-β(1906±988 pg/ml vs 14350±4798pg/ml,p＜0.01)表达水平;并提高以下细胞因子的表达:IFN-γ(59.25±10.49 pg/ml vs 18.91±9.84 pg/ml,p＜0.05),CXCL10(108.4±5.46 pg/ml vs 65.88±6.39 pg/ml,p＜0.01)。
结论:
1.伊洛前列素对博来霉素诱导小鼠肺纤维化具有明显的保护作用,降低死亡率、肺泡炎、肺泡破坏程度及纤维化程度。
2.伊洛前列素的保护作用主要是通过抑制IL-6、TNF-α和TGF-β等细胞因子表达。
3.另外伊洛前列素可通过提高IFN-γ、CXCL10、CXCL11的表达起保护作用。
Objective
●To investigate the interventional effectiveness of Iloprost on Bleomycin-induced pulmonary fibrosis in mice.
●To further explore the mechanisms of the preventive role of Iloprost on bleomycin-induced pulmonary fibrosis in mice.
Method
●The BPF model was established by a single dosage of 2mg/kg bleomycin intra-tracheal injection.Single dosage of 200ug/kg Iloprost intraperitoneal injection was given to the mice.
●The effectiveness was evaluated by the weight curve and survival rate. The fibrosis degree was determined biochemically by hydroxyproline assay in lung tissue,Ashcroft' scoring pathologically by using HE and Masson Trichrome stained lung tissue,alveolar septal thickening measurement and physical index.
●The expression of the cytokines and chemokines in lung tissue was assayed by semi-quantitative RT-PCR.
●ELISA kits was used to evaluate the cytokines and chemokines in BALF at protein level.
Result
●Compare to the mice administrated by bleomycin,there was significant protection in BPF mice treated with iloprost in several aspects:weight (p＜0.05),survival rate(90%vs 40%,p＜0.01),hydroxyproline content (56.04±2.23 ug/ml vs 77±6.01ug/ml,p＜0.05),Ashcroft' scoring (3.35±0.54 vs 5.64±0.18,p＜0.01),alveolar septal thickening (23.03±4.91 vs 56.12±4.06,p＜0.01),compliance(0.02015±0.00074 ml/cmH2O vs 0.01448±0.00178ml/cmH2O,p＜0.05) and elastance (49.96±1.83 cmH2O/ml vs 86.84±13.13cmH2O/ml,p＜0.01) of the lung tissue.
●The mRNA expression of the cytokines tested,IL-6(0.75±0.33 vs 1.67±0.22,p＜0.05),TNF-α(0.28±0.02 vs 0.44±0.05,p＜0.05),TGF-β(0.90±0.10 vs 1.26±0.07,p＜0.05) was significantly down-regulated in the lung tissues from mice treated with iloprost.The expression of IFN-y (0.90±0.10 vs 1.26±0.07,p＜0.05),CXCL10(1.03±0.09 vs 0.76±0.03, p＜0.05),CXCL11(0.35±0.04 vs 0.22±0.02,p＜0.05) was significantly up-regulated.
●The up-regulated expression of IFN-γ(59.25±10.49 vs 18.91±9.84 pg/ml,p＜0.05),CXCL10(108.4±5.46 vs 65.88±6.39 pg/ml,p＜0.01) and down-regulated expression of IL-6(26.5±4.04 vs 131.5±38.21 pg/ml,p＜0.05),TGF-β(1906±988 vs 14350±4798pg/ml,p＜0.01) was found in BALF from mice treated with iloprost.
Conclusion
●The mortality and pulmonary fibrosis degree were significantly reduced by the intrapedtoneal injection of Iloprost.
●The inhibition of inflammatory cytokines expression was the potential mechanism that iloprost protected from bleomycin-induced pulmonary fibrosis in mice.
●The induction of anti-angiogenesis mediators associated with upregulation of IFN-γ,including CXCL10 and CXCL11,was another potential protective mechanism of iloprost.
方法:
1.应用单次气管内注入博来霉素(2mg/kg体重)的方法复制小鼠肺纤维化模型,并通过单次腹腔内注射伊洛前列素(200ug/kg体重)来实现对小鼠肺纤维化的干预。
2.观测小鼠体重变化,生存指数,肺组织羟脯氨酸测定,病理切片Ashcroft评分及肺泡间隔厚度测定评估小鼠肺纤维化的严重程度,采用Flexivent系统评价博来霉素诱导肺纤维化小鼠肺功能改变,并评价伊洛前列素的干预作用。
3.通过半定量RT-PCR测定肺组织中细胞因子和趋化因子mRNA的表达水平,评价伊洛前列素对细胞因子表达的影响。
4.应用ELISA试剂盒测定BALF中细胞因子和趋化因子在蛋白水平的表达,评价伊洛前列素对细胞因子表达的影响。
结果:
1.伊洛前列素组小鼠与博来霉素组相比,在如下方面存在显著性差异:气管内注药后第6至第18天平均体重(p＜0.05),生存指数(90%vs 40%,p＜0.01),肺组织羟脯氨酸测定(56.04±2.23 ug/ml vs 77±6.01ug/ml,p＜0.05),肺纤维化Ashcroft评分(3.35±0.54 vs 5.64±0.18,p＜0.01),肺泡间隔厚度测定(23.03±4.91 vs 56.12±4.06,p＜0.01),小鼠肺组织弹性(49.96 cmH20/ml±1.83 vs 86.84±13.13cmH20/ml,p＜0.01),肺组织顺应性(0.02015±0.00074 ml/cmH20 vs 0.01448±0.00178ml/cmH20,p＜0.05),均显示伊洛前列素治疗组优于博来霉素组。
2.伊洛前列素组与博来霉素组相比,可显著降低以下细胞因子mRNA表达水平:IL-6(0.75±0.33 vs 1.67±0.22,p＜0.05),TNF-α(0.28±0.02 vs0.44±0.05,p＜0.05),TGF-β(0.90±0.10 vs 1.26±0.07,p＜0.05);并可显著提高以下细胞因子表达水平:IFN-γ(0.90±0.10 vs 1.26±0.07,p＜0.05),CXCL10(1.03±0.09 vs 0.76±0.03,p＜0.05),CXCL11(0.35±0.04 vs 0.22±0.02,p＜0.05)。
3.在蛋白水平伊洛前列素可影响BALF中以下细胞因子的表达:降低IL-6(26.5±4.04 pg/ml vs 131.5±38.21pg/ml,p＜0.05)和TGF-β(1906±988 pg/ml vs 14350±4798pg/ml,p＜0.01)表达水平;并提高以下细胞因子的表达:IFN-γ(59.25±10.49 pg/ml vs 18.91±9.84 pg/ml,p＜0.05),CXCL10(108.4±5.46 pg/ml vs 65.88±6.39 pg/ml,p＜0.01)。
结论:
1.伊洛前列素对博来霉素诱导小鼠肺纤维化具有明显的保护作用,降低死亡率、肺泡炎、肺泡破坏程度及纤维化程度。
2.伊洛前列素的保护作用主要是通过抑制IL-6、TNF-α和TGF-β等细胞因子表达。
3.另外伊洛前列素可通过提高IFN-γ、CXCL10、CXCL11的表达起保护作用。
Objective
●To investigate the interventional effectiveness of Iloprost on Bleomycin-induced pulmonary fibrosis in mice.
●To further explore the mechanisms of the preventive role of Iloprost on bleomycin-induced pulmonary fibrosis in mice.
Method
●The BPF model was established by a single dosage of 2mg/kg bleomycin intra-tracheal injection.Single dosage of 200ug/kg Iloprost intraperitoneal injection was given to the mice.
●The effectiveness was evaluated by the weight curve and survival rate. The fibrosis degree was determined biochemically by hydroxyproline assay in lung tissue,Ashcroft' scoring pathologically by using HE and Masson Trichrome stained lung tissue,alveolar septal thickening measurement and physical index.
●The expression of the cytokines and chemokines in lung tissue was assayed by semi-quantitative RT-PCR.
●ELISA kits was used to evaluate the cytokines and chemokines in BALF at protein level.
Result
●Compare to the mice administrated by bleomycin,there was significant protection in BPF mice treated with iloprost in several aspects:weight (p＜0.05),survival rate(90%vs 40%,p＜0.01),hydroxyproline content (56.04±2.23 ug/ml vs 77±6.01ug/ml,p＜0.05),Ashcroft' scoring (3.35±0.54 vs 5.64±0.18,p＜0.01),alveolar septal thickening (23.03±4.91 vs 56.12±4.06,p＜0.01),compliance(0.02015±0.00074 ml/cmH2O vs 0.01448±0.00178ml/cmH2O,p＜0.05) and elastance (49.96±1.83 cmH2O/ml vs 86.84±13.13cmH2O/ml,p＜0.01) of the lung tissue.
●The mRNA expression of the cytokines tested,IL-6(0.75±0.33 vs 1.67±0.22,p＜0.05),TNF-α(0.28±0.02 vs 0.44±0.05,p＜0.05),TGF-β(0.90±0.10 vs 1.26±0.07,p＜0.05) was significantly down-regulated in the lung tissues from mice treated with iloprost.The expression of IFN-y (0.90±0.10 vs 1.26±0.07,p＜0.05),CXCL10(1.03±0.09 vs 0.76±0.03, p＜0.05),CXCL11(0.35±0.04 vs 0.22±0.02,p＜0.05) was significantly up-regulated.
●The up-regulated expression of IFN-γ(59.25±10.49 vs 18.91±9.84 pg/ml,p＜0.05),CXCL10(108.4±5.46 vs 65.88±6.39 pg/ml,p＜0.01) and down-regulated expression of IL-6(26.5±4.04 vs 131.5±38.21 pg/ml,p＜0.05),TGF-β(1906±988 vs 14350±4798pg/ml,p＜0.01) was found in BALF from mice treated with iloprost.
Conclusion
●The mortality and pulmonary fibrosis degree were significantly reduced by the intrapedtoneal injection of Iloprost.
●The inhibition of inflammatory cytokines expression was the potential mechanism that iloprost protected from bleomycin-induced pulmonary fibrosis in mice.
●The induction of anti-angiogenesis mediators associated with upregulation of IFN-γ,including CXCL10 and CXCL11,was another potential protective mechanism of iloprost.
引文
1.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.This joint statement of the american thoracic society(ats),and the european respiratory society(ers) was adopted by the ats board of directors,June 2001 and by the ers executive committee,June 2001.Am J Respir Crit Care Med 2002;165:277-304.
2.Taylor DA,du Bois RM.Idiopathic interstitial pneumonias:A re-appraisal of idiopathic pulmonary fibrosis.Int J Tuberc Lung Dis 2001;5:1086-1098.
3.Michaelson JE,Aguayo SM,Roman J.Idiopathic pulmonary fibrosis:A practical approach for diagnosis and management.Chest 2000;118:788-794.
4.Nagai S,Kitaichi M,Hamada K,Nagao T,Hoshino Y,Miki H,Izumi T.Hospital-based historical cohort study of 234 histologically proven Japanese patients with ipf.Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-214.
5.Selman M,King TE,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
6.Raghu G,Weycker D,Edelsberg J,Bradford WZ,Oster G Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2006;174:810-816.
7.Noble PW.Idiopathic pulmonary fibrosis:Natural history and prognosis.Clin Chest Med 2006;27:S11-16,v.
8.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
9.Vasakova M,Striz I,Slavcev A,Jandova S,Dutka J,Terl M,Kolesar L,Sulc J.Correlation of il-1 alpha and il-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis.Scand J Immunol 2007;65:265-270.
10.Ziora D.[serum biomarkers in idiopathic pulmonary fibrosis].Pneumonol Alergol Pol 2007;75:268-272.
11.Tsoutsou PG,Gourgoulianis Kl,Petinaki E,Germenis A,Tsoutsou AG Mpaka M,Efremidou S,Molyvdas PA.Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis.Respir Med 2006;100:938-945.
12.Vasakova M,Striz I,Slavcev A,Jandova S,Kolesar L,Sulc J.Th1/th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis.Tissue Antigens 2006;67:229-232.
13.Millar AB.11-10:Another therapeutic target in idiopathic pulmonary fibrosis?Thorax 2006;61:835-836.
14.Uhal BD,Kim JK,Li X,Molina-Molina M.Angiotensin-tgf-beta 1 crosstalk in human idiopathic pulmonary fibrosis:Autocrine mechanisms in myofibroblasts and macrophages.Curr Pharm Des 2007;13:1247-1256.
15.Tzortzaki EG,Antoniou KM,Zervou Ml,Lambiri I,Koutsopoulos A,Tzanakis N,Plataki M,Maltezakis G Bouros D,Siafakas NM.Effects of antifibrotic agents on tgf-beta1,ctgf and ifn-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med 2007;101:1821-1829.
16.Pilewski JM,Liu L,Henry AC,Knauer AV,Feghali-Bostwick CA.Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition.Am J Pathol 2005;166:399-407.
17.Pierce EM,Carpenter K,Jakubzick C,Kunkel SL,Evanoff H,Flaherty KR,Martinez FJ,Toews GB,Hogaboam CM.Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to cc chemokine ligand 21.Eur Respir J 2007;29:1082-1093.
18.Nakayama S,Mukae H,Ishii H,Kakugawa T,Sugiyama K,Sakamoto N,Fujii T,Kadota J,Kohno S.Comparison of balf concentrations of ena-78 and ip10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.Respir Med 2005;99:1145-1151.
19.Papiris SA,Kollintza A,Karatza M,Manali ED,Sotiropoulou C,Milic-Emili J,Roussos C,Daniil Z.Cd8+ t lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis.J Inflamm(Lond) 2007;4:14.
20.Murata K,Ota S,Niki T,Goto A,Li CP,Ruriko UM,Ishikawa S,Aburatani H,Kuriyama T,Fukayama M.P63-key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis.Exp Mol Pathol 2007;83:367-376.
21.Feghali-Bostwick CA,Tsai CG,Valentine VG Kantrow S,Stoner MW,Pilewski JM,Gadgil A,George MP,Gibson KF,Choi AM,et al.Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis.J Immunol 2007;179:2592-2599.
22.Selman M,Pardo A.Role of epithelial cells in idiopathic pulmonary fibrosis:From innocent targets to serial killers.Proc Am Thorac Soc 2006;3:364-372.
23.Myers JL,Selman M.Respiratory epithelium in usual interstitial pneumonia/idiopathic pulmonary fibrosis:Spark or destructive flame?Am J Respir Crit Care Med 2004;169:3-5.
24.Selman M,Pardo A.The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis.Am J Respir Cell Mol Biol 2003;29:S93-97.
25.Moodley YP,Scaffidi AK,Misso NL,Keerthisingam C,McAnulty RJ,Laurent GJ,Mutsaers SE,Thompson PJ,Knight DA.Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.Am J Pathol 2003;163:345-354.
26.Nadrous HF,Ryu JH,Douglas WW,Decker PA,Olson EJ.Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis.Chest 2004;126:438-446.
27.Strieter RM,Starko KM,Enelow Rl,Noth I,Valentine VG Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;170:133-140.
28.O'Connor TM,Bredin CP.Interferon-gamma toxicity in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;169:428.
29.Gharaee-Kermani M,Hu B,Phan SH,Gyetko MR.Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis:Focus on tgfbeta signaling and the myofibroblast.Curr Med Chem 2009;16:1400-1417.
30.Raghu G,Brown KK,Bradford WZ,Starko K,Noble PW,Schwartz DA,King TE,Jr.A placebo-controlled trial of interferon gamma-1 b in patients with idiopathic pulmonary fibrosis.N Engl J Med 2004;350:125-133.
31.Selman M,Thannickal VJ,Pardo A,Zisman DA,Martinez FJ,Lynch JP,3rd.Idiopathic pulmonary fibrosis:Pathogenesis and therapeutic approaches.Drugs 2004;64:405-430.
32.Clark JG,Kostal KM,Marino BA.Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters.Presence of a factor in lung that increases fibroblast prostaglandin e2 and camp and suppresses fibroblast proliferation and collagen production.J Biol Chem 1982;257:8098-8105.
33.Clark JG,Kostal KM,Marino BA.Bleomycin-induced pulmonary fibrosis in hamsters.An alveolar macrophage product increases fibroblast prostaglandin e2 and cyclic adenosine monophosphate and suppresses fibroblast proliferation and collagen production.J Clin Invest 1983,72:2082-2091.
34.Ogushi F,Endo T,Tani K,Asada K,Kawano T,Tada H,Maniwa K,Sone S.Decreased prostaglandin e2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis.Int J Exp Pathol 1999;80:41-49.
35.Jenkins G,Hart SL,Hodges RJ,Meng QH,Kinnon C,Laurent GJ,McAnulty RJ.Cyclooxygenase-2 overexpression,using an integrin-targeted gene delivery system(the lid vector),inhibits fibroblast proliferation in vitro and leads to increased prostaglandin e(2) in the lung.Chesf 2002;121:102S-104S.
36.Phan SH,McGarry BM,Loeffler KM,Kunkel SL.Binding of leukotriene c4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro.Biochemistry 1988;27:2846-2853.
37.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates collagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
38.Charbeneau RP P-GM.Eicosanoids:Mediators and therapeutic targets in fibrotic lung disease.Clin Sci(Lond) 2005;108:479-491.
39.Borok Z GA,Buhl R,et al.Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
40.Wilbom J,Crofford LJ,Burdick MD,Kunkel SL,Strieter RM,Peters-Golden M.Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin e2 and to express cyclooxygenase-2.J Clin Invest 1995;95:1861-1868.
41.Keerthisingam CB JR,Harrison NK.Hemandez-Rodriguez NA.Booth H.Laurent GJ,Hart SL,Foster ML,McAnulty RJ.Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.Am J Pathol 2001;158:1411-1422.
42.Vancheri C SM,Tomaselli V,et al.Different expression of tnf-alpha receptors and prostaglandin e(2) production in normal and fibrotic lung fibroblasts:Potential implications for the evolution of the inflammatory process.Am J Respir Cell Mol Biol 2000;22:628-634.
43.Huang S,Wettlaufer SH,C.Hogaboam DMA,Peters-Golden M,February 1 L-L. Prostaglandin e2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via e prostanoid 2 receptor and camp signaling.Am J Physiol Lung Cell Mol Physiol,2007;292:L405-413.
44.R.J.Hodges RGJ,C.P.D.Wheeler-Jones,D.M.Copeman,S.E.Bottoms,G J.Bellingan,C.B.Nanthakumar,G J.Laurent,S.L.Hart,M.L.Foster,et al.Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin e2 production.Am J Pathol 2004;165:1663-1676.
45.Kohyama T,Ertl RF,Valenti V,Spurzem J,Kawamoto M,Nakamura Y,Veys T,Allegra L,Romberger D,Rennard SI.Prostaglandin e(2) inhibits fibroblast chemotaxis.Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-1263.
46.Vibha Lama BBM,Paul Christensen,Galen B.Toews,and Marc Peters-Golden Prostaglandin e2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.Am J Respir Cell Mol Biol 2002;27.
47.Kolodsick JE,Peters-Golden M,Larios J,Toews GB,Thannickal VJ,Moore BB.Prostaglandin e2 inhibits fibroblast to myofibroblast transition via e.Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.Am J Respir Cell Mol Biol 2003;29:537-544.
48.Zhang A,Wang MH,Dong Z,Yang T.Prostaglandin e2 is a potent inhibitor of epithelial-to-mesenchymal transition:Interaction with hepatocyte growth factor.Am J Physiol Renal Physiol 2006;291:F1323-1331.
49.Failla M GT,Mazzon E,Fruciano M,Fagone E,Gili E,Barera A,La Rosa C,Conte E,Crimi N,Cuzzocrea S,Vancheri C.16,16-dimethyl prostaglandin e2 efficacy on prevention and protection from bieomycin-induced lung injury and fibrosis.Am J Respir Cell Mol Biol 2008.
50.Cruz-Gervis R SA,Dworski R,Lane KB,Loyd JE,Pierson R,King G,Brigham K.Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis..Respir Res 2002;3:17.
51.Kern Lovgren A JL,Hartney JM,Parsons KK,Audoly LP,FitzGerald GA,Tilley SL,and Koller BH.Cox-2-derived prostacyclin protects against bieomycin-induced pulmonary fibrosis..Am J Physiol Lung Cell Mol Physiol 2006,291:L144-L156.
52.Koichiro Kamio XL,Hisatoshi Sugiura,Shinsaku Togo,Tetsu Kobayashi,Shinsaku Kawasaki,Xingqi Wang,Lijun Mao,Youngsoo Ahn,Cory Hogaboam,Myron L.Toews,and Stephen I.Rennard Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the camp-pka pathway.Am J Respir Cell Mol Biol 2007;37.
53.Ferhana Y.AN KE,Garret A.FitzGerald,Beatrice Desvergne,Walter Wahli,David Bishop-Bailey,Timothy D.Warner,and Jane A.Mitchell Role of prostacyclin versus peroxisome proliferator-activated receptor receptors in prostacyclin sensing by lung fibroblasts.Am J Respir Cell Mol Biol 2005;34:242-246.
54.Stratton R,Shiwen X,Martini G,Holmes A,Leask A,Haberberger T,Martin GR,Black CM,Abraham D.Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.J Clin Invest 2001;108:241-250.
55.Yu H,Gallagher AM,Garfin PM,Printz MP.Prostacyclin release by rat cardiac fibroblasts:Inhibition of collagen expression.Hypertension 1997;30:1047-1053.
56.Nana-Sinkam P,Lee JD,Sotto-Santiago S,Stearman RS,Keith RL,Choudhury Q, Cool C,Parr J,Moore MD,Bull TM,et al.Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.Am J Respir Crit Care Med 2007;175:676-685.
57.Idzko M HH,van Nimwegen M,Kool M,Vos N,Hoogsteden HC,Lambrecht BN.Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.J Clin Invest 2007;117:464-472.
58.Nagao K.ea.Role of prostaglandin i2 in airway remodeling induced by repeated allergen challenge in mice..Am J Respir Cell Mol Biol 2003;29:314-320.
59.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
60.Zardi EM,Dobrina A,Amoroso A,Afeltra A.Prostacyclin in liver disease:A potential therapeutic option.Expert Opin Biol Ther 2007;7:785-790.
61.Kaneshige T,Saida Y,Tanaka R,Soda A,Fukushima A,Ida N,Takenaka M,Yamane Y.Effect of long-term administration of a prostacyclin analogue(beraprost sodium) on myocardial fibrosis in dahl rats.J Vet Med Sci 2007;69:1271-1276.
62.Nasrallah R,Hebert RL.Prostacyclin signaling in the kidney:Implications for health and disease.Am J Physiol Renal Physiol 2005;289:F235-246.
63.Lovgren AK,Jania LA,Hartney JM,Parsons KK,Audoly LP,Fitzgerald GA,Tilley SL,Koller BH.Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis.Am J Physiol Lung Cell Mol Physiol 2006;291:L144-156.
64.Skuballa W,Raduchel,B.,and Vorbruggen,H.1985.Chemistry of stable prostacyclin analogues:synthesis of Iloprost.In Prostacyclin and its stable analogue Iloprost.R.G Gryglewski and G Stock,editors.Springer-Verlag.Berlin,Germany.17-24.
65.SK H,M P-G Eicosanoid lipid mediators in fibrotic lung diseases:Ready for prime time?Chet 2006;133:1442-1445.
66.Antoniou KM,Alexandrakis MG,Siafakas NM,Bouros D.Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis.Sarcoidosis Vase Diffuse Lung Dis 2005;22:91-104.
67.Christmas RJSaP.Revisiting prostacyclin:New directions in pulmonary fibrosis and inflammation Am J Physiol Lung Cell Mol Physiol 2006,291.L142-L143.
68.Hattori N DJ,Sisson TH,Liu H,Moore BB,Pandrangi RG,Simon RH,Drew AF.Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.J Clin Invest 1988;106:1341-1350.
69.Voltz JW,Card JW,Carey MA,DeGraff LM,Ferguson CD,Flake GP,Bonner JC,Korach KS,Zeldin DC.Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis.Am J Respir Cell Mol Biol 2008;39:45-52.
70.Nagase T,Uozumi N,Ishii S,Kita Y,Yamamoto H,Ohga E,Ouchi Y,Shimizu T.A pivotal role of cytosolic phospholipase a2 in bleomycin-induced pulmonary fibrosis.Nature Medicine 2002;8:480-484.
71.Waseda Y YM,Nishizawa Y,Inuzuka K,Takato H,Ichikawa Y,Tagami A,Fujimura M,Nakao S.Angiotensin ii type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.Respir Res 2008;9:43.
72.Moore BB BM,White ES,Green ME,Herrygers AB,Wilke CA,Toews GB,and Peters-Golden M..Bleomycin-induced e prostanoid receptor changes alter fibroblast responses to prostaglandin e2.J Immunol 2005;174:5644-5649.
73.James H HJaLJ.High dose continuous infusion of bleomycin in mice:A new model for drug-induced pulmonary fibrosis..J Pharmo Exp Thera 1987;243:1185-1194.
74.R.Dembinski WB,D.Henzler,A.Rott,R.Bensberg,R.Kuhlen,and R.Rossaint.Cardiopulmonary effects of iloprost in experimental acute lung injury.Eur Respir J 2005;25:81-87.
75.Ashcroft T SJ,Timbrell V.Simple method of estimating severity of pulmonary fibrosis on a numerical scale..J Clin Pathol 1988;41:467-470.
76.Beller TC FD,Maekawa A,Lam BK,Austen KF,and Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis..Proc Natl Acad Sci USA 2004;101:3047-3052.
1.Gallagher AM,Yu H,Printz MP.Bradykinin-induced reductions in collagen gene expression involve prostacyclin.Hypertension 1998;32:84-88.
2.Yu H,Gallagher AM,Garfin PM,Printz MP.Prostacyclin release by rat cardiac fibroblasts:Inhibition of collagen expression.Hypertension 1997;30:1047-1053.
3.Stratton R,Shiwen X,Martini G,Holmes A,Leask A,Haberberger T,Martin GR,Black CM,Abraham D.Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.J Clin Invest 2001;108:241-250.
4.RL.NRaHb.Reduced ip receptors in stz-induced diabetic rat kidneys and high-glucose-treated mesangial cells.Am J Physiol Renal Physiol 2004;287:F673-F681.
5.Stratton R,Rajkumar V,Ponticos M,Nichols B,Shiwen X,Black CM,Abraham DJ,Leask A.Prostacyclin derivatives prevent the fibrotic response to tgf-beta by inhibiting the ras/mek/erk pathway.FASEB J 2002;16:1949-1951.
6.Felix Chua JG and Geoffrey J.Laurent.Pulmonary fibrosis:Searching for model answers.Am J Respir Cell Mol Biol 2005;33:9-13.
7.Kaminski J AJ,Pittet F,Zuo F,Griffiths MJD,Morris D,Huang X,Sheppard D,Heller RA.Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis.Proc Natl Acad Sci USA 2000;97:1778-1783.
8.Saito F TS,Inoue K,Miyamoto K,Nakano Y,Ogawa Y,Yamada W,Shiraishi Y,Hasegawa N,Fujishima S,Takano H,Ishizaka A.Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice.Am J Respir Cell Mol Biol 2008;38:566-571.
9.Moodley YP,Scaffidi AK,Misso NL,Keerthisingam C,McAnulty RJ,Laurent GJ,Mutsaers SE,Thompson PJ,Knight DA.Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.Am J Pathol 2003;163:345-354.
10.Kim JH,Kim HY,Kim S,Chung JH,Park WS,Chung DH.Natural killer t(nkt) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.Am J Pathol 2005;167:1231-1241.
11.Baran CP OJ,McMaken S,Newland CA,O'Brien JM Jr,Hunter MG Bringardner BD,Monick MM,Brigstock DR,Stromberg PC,Hunninghake GW,Marsh CB.Important roles for m-csf,ccl2 and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis.Am J Respir Crit Care Med 2007;176:78-89.
12.B.B.Moore MP-G P.J-Christensen,V.Lama,W.A.Kuziel,R.Paine III,and G B.Toews.Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by mcp-1/ccr2 and mediated by pge2.Am J Physiol Lung Cell Mol Physiol 2003;284:L342-L349.
13.Wasmuth HE,Lammert F,Zaldivar MM,Weiskirchen R,Hellerbrand C,Scholten D,Berres ML,Zimmermann H,Streetz KL,Tacke F,et al.Anti-fibrotic effects of cxcl9 and its receptor cxcr3 in livers of mice and humans.Gastroenterology 2009.
14.Jiang D,Liang J,Hodge J,Lu B,Zhu Z,Yu S,Fan J,Gao Y,Yin Z,Homer R,et al. Regulation of pulmonary fibrosis by chemokine receptor cxcr3.J Clin Invest 2004;114:291-299.
15.Tager AM,Kradin RL,LaCamera P,Bercury SD,Campanella GS,Leary CP,Polosukhin V,Zhao LH,Sakamoto H,Blackwell TS,et al.Inhibition of pulmonary fibrosis by the chemokine ip-10/cxcl10.Am J Respir Cell Mol Biol 2004;31:395-404.
16.Nakayama S,Mukae H,Ishii H,Kakugawa T,Sugiyama K,Sakamoto N,Fujii T,Kadota J,Kohno S.Comparison of balf concentrations of ena-78 and ip10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.Respir Med 2005;99:1145-1151.
17.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
18.Christmas RJSaP.Revisiting prostacyclin:New directions in pulmonary fibrosis and inflammation Am J Physiol Lung Cell Mol Physiol 2006;291:L142-L143.
19.Society.ATSER.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med 2002;165:227-304.
20.Huang M sS,Zhu LX,Keane MP,Luo.J,Zhang L,et al.Ⅱ-7 inhibits fibroblast tgf-beta production and signaling in pulmonary fibrosis.J Clin Invest 2002;109:931-937.
21.Nakao A FM,Matsumura R,Kumano K,Saito Y,Miyazono K,et al.Transient gene transsfer and expression of smad 7 prevents bleomycin-induced lung fibrosis in mice.J Clin Invest 1999;104:5-11.
22.Raghu G JW,Lockhart D,Mageto Y Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:Results of a prospective,open-label phase ii study.Am J Respir Crit Care Med 1999;159:1061-1069.
23.Piguet PF VC.Treatment by human recombinant soluble tnf receptor of pulmonary fibrosis induced by bleomycin or silica in mice.Eur Respir J 1994;7:515-518.
24.Sime PJ ORK.Fibrosis of the lung and other tissues:New concepts in pathogenesis and treatment.Clin Immunol 2001;99::308-319.
25.Molina-Molina M,Serrano-Mollar A,Bulbena O,Femandez-Zabalegui L,Closa D,Marin-Arguedas A,Torrego A,Mullol J,Picado C,Xaubet A,et al.Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin e2 synthesis.Thorax 2006;61:604-610.
26.Nogee LM DAI,Wert SE,Askin F,Hamas A,Whitsett JA..A mutation in the surfactant c protein associated with familial interstitial lung disease.N Engl J Med 2001;344:573-579.
27.Thomas AO LK,Phillips J III,Markin PM,Speer M,Schwartz DA,Gaddipati R,Marvnev A,Johnson J,Roberts R,et al..Heterozygosity for a surfactant protein c mutation associated with usual interstitial pneumonia and cellular non-specific interstitial pneumonia in one kindred.Am J Respir Crit Care Med 2002;165:1322-1328.
28.Marney A,Lane KB,Phillips JA,3rd,Riley DJ,Loyd JE.Idiopathic pulmonary fibrosis can be an autosomal dominant trait in some families.Chest 2001;120:56S.
29.Stewart JP EJ,Ross AJ,et al..The detection of epstein-barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis..Am J Respir Crit Care Med 1999;159:1336-1341.
30.Yi-Wei Tang JEJ,Philip J.Browning,Roberto A.Cruz-Gervis,Angela Davis,Barney S.raham.Kenneth L.Brigham,John A.Oates Jr.,James E.Loyd,and Arlene A.Stecenko.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.JOURNAL OF CLINICAL MICROBIOLOGY 2003;June 2633-2640.
31.Gauldie J,Kolb M,Sime PJ.A new direction in the pathogenesis of idiopathic pulmonary fibrosis?Respir Res 2002;3:1.
32.Pardo A,Selman M.Idiopathic pulmonary fibrosis:New insights in its pathogenesis.Int J Biochem Cell Biol 2002;34:1534-1538.
33.Lok SS,Egan JJ.Viruses and idiopathic pulmonary fibrosis.Monaldi Arch Chest Dis 2000;55:146-150.
34.Tang YW,Johnson J,Cruz-Gervis R,Graham B,Brigham K,Oates J,Loyd J,Stecenko A.Increased detection of herpesvirus DNA in idiopathic pulmonary fibrosis.Chest 2001;120:74S-75S.
35.Lok SS,Stewart JP,Kelly BG,Hasleton PS,Egan JJ.Epstein-barr virus and wild p53 in idiopathic pulmonary fibrosis.Respir Med 2001;95:787-791.
36.Kelly BG,Lok SS,Hasleton PS,Egan JJ,Stewart JP.A rearranged form of epstein-barr virus DNA is associated with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2002;166:510-513.
37.Tang YW,Johnson JE,Browning PJ,Cruz-Gervis RA,Davis A,Graham BS,Brigham KL,Oates JA,Jr.,Loyd JE,Stecenko AA.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.J Clin Microbiol 2003;41:2633-2640.
38.Flaherty KR TW,Colby TV,Toews GB,Kazerooni EA,Gross BH,Jain A,Strawderman RL,Flint A,Lynch JP,e.t al..Histopathologic variability in usual and nonspecific interstitial pneumonias..Am J Respir Crit Care Med 2001;164:1722-1727.
39.FJ.M.Idiopathic interstitial pneumonias:Usual interstitial pneumonia versus nonspecific interstitial pneumonia.Proc Am Thorac Soc 2006;3:81-95.
40.Ando M,Miyazaki E,Fukami T,Kumamoto T,Tsuda T.lnterleukin-4-producing cells in idiopathic pulmonary fibrosis:An immunohistochemical study.Respirology 1999;4:383-391.
41.Lemjabbar H,Gosset P,Lechapt-Zalcman E,Franco-Montoya ML,Wallaert B,Harf A,Lafuma C.Overexpression of alveolar macrophage gelatinase b(mmp-9) in patients with idiopathic pulmonary fibrosis:Effects of steroid and immunosuppressive treatment.Am J Respir Cell Mol Biol 1999;20:903-913.
42.Liu L,Zong Z,Li Z.[changes on the protein kinase c activity of alveolar macrophages in patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2000;23:397-399.
43.Ogushi F,Tani K,Endo T,Tada H,Kawano T,Asano T,Huang L,Ohmoto Y,Muraguchi M,Moriguchi H,et al.Autoantibodies to il-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis.J Med Invest 2001;48:181-189.
44.Pantelidis P,Fanning GC,Wells AU,Welsh Kl,Du Bois RM.Analysis of tumor necrosis factor-alpha,lymphotoxin-alpha,tumor necrosis factor receptor ii,and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2001;163:1432-1436.
45.Xiao L,Li ZH,Hou XM,Yu RJ.[evaluation of interleukin-13 in the serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2003;26:686-688.
46.Zorzetto M,Ferrarotti I,Trisolini R,Agli LL,Scabini R,Novo M,De Silvestri A,Patelli M,Martinetti M,Cuccia M,et al.Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2003;168:330-334.
47.Kitasato Y,Hoshino T,Okamoto M,Kato S,Koda Y,Nagata N,Kinoshita M,Koga H,Yoon DY,Asao H,et al.Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis.Am J Respir Cell Mol Biol 2004;31:619-625.
48.Collard HR MB,Flaherty KR,Brown KK,Kaner RJ,King TE Jr,Lasky JA,Loyd JE,Noth I,Olman MA,Raghu G,Roman J,Ryu JH,Zisman DA,Hunninghake GW,Colby TV,Egan JJ,Hansell DM,Johkoh T,Kaminski N,Kim DS,Kondoh Y,Lynch DA,Muller-Quernheim J,Myers JL,Nicholson AG,Selman M,Toews GB,Wells AU,Martinez FJ;Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators.Acute exacerbations of idiopathic pulmonary fibrosis-Am J Respir Crit Care Med 2007;176:636-643.
49.Dallari R,Foglia M,Paci M,Cavazza A.Acute exacerbation of idiopathic pulmonary fibrosis.Eur Respir J 2004;23:792.
50.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
51.Kohyama T LX,Kim HJ,Kobayashi T,Ertl RF,Wen FQ,Takizawa H,and Rennard
51.Prostacyclin analogs inhibit fibroblast migration..Am J Physiol Lung Cell Mol Physiol 2002;283:L428-L432.
52.Nana-Sinkam P,Lee JD,Sotto-Santiago S,Stearman RS,Keith RL,Choudhury Q,Cool C,Parr J,Moore MD,Bull TM,et al.Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.Am J Respir Crit Care Med 2007;175:676-685.
53.Jaffar Z.WKS,Roberts K.A key role for prostaglandin i2 in limiting lung mucosal th2,but not th1,responses to inhaled allergen..J Immunol 2002;169:5997-6004.
54.Nagao K.ea.Role of prostaglandin i2 in airway remodeling induced by repeated allergen challenge in mice..Am J Respir Cell Mol Biol 2003;29:314-320.
55.Chaudhary Nl,Schnapp A,Park JE.Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.Am J Respir Crit Care Med 2006;173:769-776.
56.J.W.Card JWV,M.A.Carey,J.A.Bradbury,L.M.DeGraff,F.B.Lih,J.C.Bonner,D.L.Morgan,G P.Flake,and D.C.Zeldin.Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.Am J Respir Cell Mol Biol 2007;37:300-308.
57.Fujita M YQ,Ouchi H,Harada E,Inoshima I,Kuwano K,Nakanishi Y.Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice.Antimicrob Agents Chemother 2006;50:739-743.
58.Keane MP BJ,Arenberg DA,Burdick MD,Xu ZJ,Xue YY,Strieter RM.Ifn-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.J Immunol 1999;176:7087-7095.
59.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.This joint statement of the american thoracic society(ats),and the european respiratory society(ers) was adopted by the ats board of directors,June 2001 and by the ers executive committee,June 2001.Am J Respir Crit Care Med 2002;165:277-304.
60.Murray LA,Argentieri RL,Farrell FX,Bracht M,Sheng H,Whitaker B,Beck H,Tsui P,Cochlin K,Evanoff HL,et al.Hyper-responsiveness of ipf/uip fibroblasts:Interplay between tgfbetal,il-13 and ccl2.Int J Biochem Cell Biol 2008;40:2174-2182.
61.Uhal BD,Kim JK,Li X,Molina-Molina M.Angiotensin-tgf-beta 1 crosstalk in human idiopathic pulmonary fibrosis:Autocrine mechanisms in myofibroblasts and macrophages.Curr Pharm Des 2007;13:1247-1256.
62.Tzortzaki EG,Antoniou KM,Zervou Ml,Lambiri I,Koutsopoulos A,Tzanakis N,Plataki M,Maltezakis G,Bouros D,Siafakas NM.Effects of antifibrotic agents on tgf-beta1,ctgf and ifn-gamma expression in patients with idiopathic pulmonary fibrosis.Respir Med 2007;101:1821-1829.
63.Bergeron A,Soler P,Kambouchner M,Loiseau P,Milleron B,Valeyre D,Hance AJ,Tazi A.Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for tgf-beta and il-10.Eur Respir J 2003;22:69-76.
64.Gharaee-Kermani M,Hu B,Phan SH,Gyetko MR.Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis:Focus on tgfbeta signaling and the myofibroblast.Curr Med Chem 2009;16:1400-1417.
65.Zhang K,Gharaee-Kermani M,McGarry B,Remick D,Phan SH.Tnf-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis.J Immunol 1997;158:954-959.
66.Piguet PF,Vesin C.Treatment by human recombinant soluble tnf receptor of pulmonary fibrosis induced by bleomycin or silica in mice.Eur Respir J 1994;7:515-518.
67.Ask K,Bonniaud P,Maass K,Eickelberg O,Margetts PJ,Warburton D,Groffen J,Gauldie J,Kolb M.Progressive pulmonary fibrosis is mediated by tgf-beta isoform 1 but not tgf-beta3.Int J Biochem Cell Biol 2008;40:484-495.
68.Bonniaud P,Kolb M,Gait T,Robertson J,Robbins C,Stampfli M,Lavery C,Margetts PJ,Roberts AB,Gauldie J.Smad3 null mice develop airspace enlargement and are resistant to tgf-beta-mediated pulmonary fibrosis.J Immunol 2004;173:2099-2108.
69.Branton MH,Kopp JB.Tgf-beta and fibrosis.Microbes Infect 1999;1:1349-1365.
70.McCormick LL,Zhang Y,Tootell E,Gilliam AC.Anti-tgf-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease:A model for human scleroderma.J Immunol 1999;163:5693-5699.
71.Kolb M,Margetts PJ,Gait T,Sime P,Xing Z,Schmid M.Transient transgene expression of decorin in thr lung reduces the fibrotic response to bleomycin.Am J Respir Crit Care Med 2001;163:770-777.
72.Wang Q,Wang Y,Hyde D,Gotwals P,Koteliansky V,Ryan ST.Reduction of bleomycin dnduced lung fibrosis by transformaing growth factor beta soluble receptor in hamster.Thorax 1999;54:805-812.
73.Lyer S,Gurujeyalakshmi G,Giri SN.Effects of pirfinidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther 1999;291:367-373.
74.Strieter R,Starko K,Enelow R,Noth I,Valentine V,Group IPFBS.Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;170:133-140.
75.Raghu G,Brown KK,Bradford WZ,Starko K,Noble PW,Schwartz DA,King TE,Jr.A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.N Engl J Med 2004;350:125-133.
76.Antoniou KM,Nicholson AG Dimadi M,Malagari K,Latsi P,Rapti A,Tzanakis N,Trigidou R,Polychronopoulos V,Bouros D.Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis.Eur Respir J 2006;28:496-504.
77.Gurujeyalakshmi G,Giri SN.Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis:Downregulation of tgf-beta and procollagen i and iii gene expression.Exp Lung Res 1995;21:791-808.
78.Ziesche R,Block LH.Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis.Wien Klin Wochenschr 2000;112:785-790.
79.Keane MP,Arenberg DA,Lynch JP,3rd,Whyte Rl,lannettoni MD,Burdick MD,Wilke CA,Morris SB,Glass MC,DiGiovine B,et al.The cxc chemokines,il-8 and ip-10,regulate angiogenic activity in idiopathic pulmonary fibrosis.J Immunol 1997;159:1437-1443.
80.Car BD,Meloni F,Luisetti M,Semenzato G,Gialdroni-Grassi G,Walz A.Elevated il-8 and mcp-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.Am J Respir Crit Care Med 1994;149:655-659.
81.Nakaya I,Wada T,Furuichi K,Sakai N,Kitagawa K,Yokoyama H,Ishida Y,Kondo T,Sugaya T,Kawachi H,et al.Blockade of ip-10/cxcr3 promotes progressive renal fibrosis.Nephron Exp Nephrol 2007;107:e12-21.
82.Tager AM KR,LaCamera P,Bercury SD,Campanella GS,Leary CP,Polosukhin V,Zhao LH,Sakamoto H,BIackwell TS,Luster AD.Inhibition of pulmonary fibrosis by the chemokine ip-10/cxcl10.Am J Respir Cell Mol Biol 2004;31:395-404.
83.Burdick MD ML,Keane MP,Xue YY,Zisman DA,Belperio JA,Strieter RM.Cxcl11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.Am J Respir Crit Care Med 2005;171:261-268.
84.Selman M,King TE,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
85.Antoniou KM,Tzanakis N,Tzortzaki EG Malagari K,Koutsopoulos AV,Alexandrakis M,Wells AU,Siafakas NM.Different angiogenic cxc chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients.Pulm Pharmacol Ther 2008;21:840-844.
86.MP K,JA B,TA M,BB M,DAA,RE S,MD B,SL K,RM S.Neutralization of the cxc chemokine,macrophage inflammatory protein-2,attenuates bleomycin-induced pulmonary fibrosis.J Immunol 1999;162:5511-5518.
87.Jiang D LJ,Hodge J,Lu B,Zhu Z,Yu S,Fan J,Gao Y,Yin Z,Homer R,Gerard C,Noble PW.Regulation of pulmonary fibrosis by chemokine receptor cxcr3.J Clin Invest 2004;114:291-299.
88.P P,G B,D M,MR Y,M F,B B,A B,G C,Nava S,G M.Role of the chemokine receptors cxcr3 and ccr4 in human pulmonary fibrosis.Am J Respir Crit Care Med 2006;173:310-317.
89.Capelli A,Di Stefano A,Gnemmi I,Donner CF.Ccr5 expression and cc chemokine levels in idiopathic pulmonary fibrosis.Eur Respir J 2005;25:701-707.
90.JH K,HY K,S K,JH C,WS P,DH C.Natural killer t(nkt) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.Am J Pathol 2005;167:1231-1241.
91.Izumo T,Kondo M,Nagai A.Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.Life Sci 2007,80:1882-1886.
92.Beller TC,Friend DS,Maekawa A,Lam BK,Austen KF,Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.Proc Natl Acad Sci U S A 2004;101:3047-3052.
93.Kowal-Bielecka O,Distler O,Kowal K,Siergiejko Z,Chwiecko J,Sulik A,Gay RE,Lukaszyk AB,Gay S,Sierakowski S.Elevated levels of leukotriene b4 and leukotriene e4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.Arthritis Rheum 2003;48:1639-1646.
94.Peters-Golden M,Bailie M,Marshall T,Wilke C,Phan SH,Toews GB,Moore BB.Protection from pulmonary fibrosis in leukotriene-deficient mice.Am J Respir Crit Care Med 2002;165:229-235.
95.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates collagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
96.Fujita M,Shannon JM,Morikawa O,Gauldie J,Hara N,Mason RJ.Overexpression of tumor necrosis factor-{alpha} diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-{beta}.Am J Respir Cell Mol Biol 2003;29:669-676.
97.Borok Z GA,Buhl R,et al.Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
98.Li JZ,Li ZH,Kang J,Hou XM,Yu RJ.[change of prostaglandin e2 and interleukin-12,interleukin-13 in the bronchoalveolar lavage fluid and the serum of the patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2004;27:378-380.
1.American thoracic society/european respiratory society.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med 2002;165:227-304.
2.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
3.Taylor DA,du Bois RM.Idiopathic interstitial pneumonias:A re-appraisal of idiopathic pulmonary fibrosis.IntJTuberc Lung Dis 2001;5:1086-1098.
4.Michaelson JE,Aguayo SM,Roman J.Idiopathic pulmonary fibrosis:A practical approach for diagnosis and management.Chest 2000;118:788-794.
5.Nagai S,Kitaichi M,Hamada K,Nagao T,Hoshino Y,Miki H,Izumi T.Hospital-based historical cohort study of 234 histologically proven Japanese patients with ipf.Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-214.
6.Raghu G,Weycker D,Edelsberg J,Bradford WZ,Oster G Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2006;174:810-816.
7.Noble PW.Idiopathic pulmonary fibrosis:Natural history and prognosis.Clin Chest Med 2006;27:S11-16,v.
8.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
9.Kaneshige T,Saida Y,Tanaka R,Soda A,Fukushima A,Ida N,Takenaka M,Yamane Y.Effect of long-term administration of a prostacyclin analogue(beraprost sodium) on myocardial fibrosis in dahl rats.J Vet Med Sci 2007;69:1271-1276.
10.Yokoyama C,Yabuki T,Shimonishi M,Wada M,Hatae T,Ohkawara S,Takeda J,Kinoshita T,Okabe M,Tanabe T.Prostacyclin-deficient mice develop ischemic renal disorders,including nephrosclerosis and renal infarction.Circulation 2002;106:2397-2403.
11.Zardi EM,Dobrina A,Amoroso A,Afeltra A.Prostacyclin in liver disease:A potential therapeutic option.Expert Opin Biol Ther 2007;7:785-790.
12.RP C,M.P-G Eicosanoids:Mediators and therapeutic targets in fibrotic lung disease.Clin Sci(Lond) 2005;108:479-491.
13.Bhattacharya M,Peri,K.G,Almazan,G et al.Nuclear localization of prostaglandin e2 receptors.Proc Natl Acad Sci U S A 1998;95:15792-15797.
14.Narumiya S,Sugimoto,Y.and Ushikubi,F.Prostanoid receptors:Structures,properties,and functions.Physiol Rev 1999;79:1193-1226.
15.Lynch KR,O'Neill,G.P.,Liu,Q.et al.(1999)(London) 399,.Characterization of the human cysteinyl leukotriene receptor..Nature 1999;399:789-793.
16.Heise CE,O'Dowd,B.R,Figueroa,D.J.et al.Characterization of the human cysteinyl leukotriene 2 receptor..J Biol Chem 2000;275:30531-30536.
17.Yokomizo T,Izumi,T.,Chang,K.,Takuwa,Y.and Shimizu,T.A g-protein-coupled receptor for leukotriene b4 that mediates chemotaxis.Nature(London) 1997;387:620-624.
18.Yokomizo T,Kato,K.,Terawaki,K.,Izumi,T.and Shimizu,T.A second leukotriene b4 receptor,blt2:A new therapeutic target in inflammation and immunological disorders..J Exp Med 2000;192:421-432.
19.Martin TR,Pistorese,B.P.,Chi,E.Y,Goodman,R.B.and Matthay,M.A.Effects of leukotriene b4 in the human lung:Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.J Clin /nvest 1989;84:1609-1619.
20.Laitinen LA,Laitinen,A.,Haahtela,T.,Vilkka,V.,Spur,B.W.and Lee,T.H.Leukotriene e4 and granulocytic infiltration into asthmatic airways..Lancet 1993;341:989-990.
21.Cyr MMaD,J.A.Systemic aspects of allergic disease:The role of the bone marrow.Curr Opin Immunol 2001;13:727-732.
22.Pasquaie DaC,G Lipoxygenase products regulate proliferation of granulocytemacrophage progenitors.Exp Hematol 1993;21:1361-1365.
23.Nagy L,Lee,T.H.,Goetzl,E.J.,Pickett,W.C.and Kay,A.B..Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products.Clin Exp Immunol 1982;47:541-547.
24.Pedersen KE,Bochner,B.S.and Undem,B.J.Cysteinyl leukotrienes induce p-selectin expression in human endothelial cells via a non-cyslt1 receptormediated mechanism.J Pharmacol Exp Ther 1997;281:655-662.
25.Hebert MJ,Takano,T.,Holthofer,H.and Brady,H.R.Sequential morphologic events during apoptosis of human neutrophils:Modulation by lipoxygenase-derived eicosanoids.J Immunol 1996;157:3105-3115.
26.Lee E,Robertson,T.,Smith,J.and Kilfeather,S..Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals.Am J Respir Crit Care Med 2000;161:1881-1886.
27.Kane GC,Pollice,M.,Kim,C.J.et al.A controlled trial of the effect of the 5-lipoxygenase inhibitor,zileuton,on lung inflammation produced by segmental antigen challenge in human beings..J Allergy Clin Immunol 1996;97:646-654.
28.Denizot Y.Prostaglandin e2 regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells.Biochim Biophys Acta 1999;1450:444-451.
29.Zeidler R,Csanady,M.,Gires,O.,Lang,S.,Schmitt,B.and Wollenberg,B.Tumor cell-derived prostaglandin e2 inhibits monocyte function by interfering with ccr5 and mac-1.FASEB J 2000;14:661-668.
30.Irvin CG Tu,Y.P.,Sheller,J.R.and Funk,C.D.5-lipoxygenase products are necessary for ovalbumininduced airway responsiveness in mice.Am J Physiol 1997;272:L1053-L1058.
31.Robbiani DF,Finch,R.A.,Jager,D.,Muller,W.A.,Sartorelli,A.C.and Randolph,G J..The leukotriene c4 transporter mrpl regulates ccl19(mip-3p,elc)-dependent mobilization of dendritic cells to lymph nodes..Cell(Cambridge,Mass) 2000;103:757-768.
32.Tager AM,Bromley,S.K.and Medoff,B.D.et.al.Leukotriene b4 receptor bltl mediates early effector t cell recruitment..Nat Immunol 2003;4:982-990
33.Hojo M,Suzuki,M.,Maghni,K.,Hamid,Q.,Powell,W.S.and Martin,J.G Role of cysteinyl leukotrienes in cd4+ t cell-driven late allergic airway responses.J Pharmacol Exp Ther 2000;293:410-416.
34.Tohda Y,Nakahara,H.,Kubo,H.,Haraguchi,R.,Fukuoka,M.and Nakajima,S.Effects of ono-1078(pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma..Clin Exp Allergy 1999;29:1532-1536.
35.Underwood DC,Osborn,R.R.,Newsholme,S.J.,Torphy,T.J.and Hay,D.W..Persistent airway eosinophilia after leukotriene(It) d4 administration in the guinea pig:Modulation by the Itd4 receptor antagonist,pranlukast,or an interleukin-5 monoclonal antibody..Am J Respir Crit Care Med 1996;154:850-857
36.Peters-Golden M,Bailie,M.,Marshall,T.et al.Protection from pulmonary fibrosis in leukotrienedeficient mice..Am J Respir Crit Care Med 2002;165:229-235.
37.Bonta ILaP,M.J..Immunomodulatory-antiinflammatory functions of e-type prostaglandins:Minireview with emphasis on macrophage-mediated effects.J Immunopharmacol 1982;4:103-109.
38.Steinbrink K,Paragnik,L,Jonuleit,H.,Tuting,T.,Knop,J.and Enk,A.H.Induction of dendritic cell maturation and modulation of dendritic cellinduced immune responses by prostaglandins..Arch Dermatol Res 2000;292:437-445.
39.Kambayashi T,Wallin,R.P.and Ljunggren,H.G Camp-elevating agents suppress dendritic cell function.J Leukoc Biol 2001;70:903-910.
40.Betz MaF,B.S.(1991) 146,.Prostaglandin e2 inhibits production of th1 lymphokines but not of th2 lymphokines.J Immunol 1991;146:108-113.
41.Peebles J,R.S.,Dworski,R.,Collins,R.D.et al.Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice..Am J Respir CritCare Med 2000;162:676-681.
42.Brach MA,de Vos,S.,Arnold,C,Gruss,H.J.,Mertelsmann,R.and Herrmann,F.Leukotriene b4 transcriptionally activates interleukin-6 expression involving nf-κb and nf-il6..Eur J Immunol 1992;22:2705-2711.
43.Christman JW,Christman,B.W.,Shepherd,V.L.and Rinaldo,J.E.Regulation of alveolar macrophage production of chemoattractants by leukotriene b4 and prostaglandin e2.Am J Respir Cell Mol Biol 1991;5.
44.Dubois CM,Bissonnette,E.and Rola-Pleszczynski,M.Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor Autoregulatory role of leukotriene b4.Am RevRespir Dis 1989;139:1257-1264.
45.Phan SH,McGarry,B.M.,Loeffler,K.M.and Kunkel.S.L..Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites.J Leukoc Biol 1987;42:106-113.
46.Prins BA,Hu,R.M.,Nazario,B.et al..Prostaglandin e2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells.J Biol Chem 1994;269:11938-11944.
47.Rajah R,Nunn,S.E.,Herrick,D.J.,Grunstein,M.M.and Cohen,P.Leukotriene d4 induces mmp-1,which functions as an igfbp protease in human airway smooth muscle cells.Am J Physiol 1996;271:L1014-L1022.
48.Kunkel SL,Spengler,M.,May,M.A.,Spengler,R.,Larrick,J.and Remick,D.Prostaglandin e2 regulates macrophage-derived tumor necrosis factor gene expression..J Biol Chem 1988;263:5380-5384.
49.Ham EA,Soderman,D.D.,Zanetti,M.E.,Dougherty.H.W.,McCauley,E.and Kuehl,Jr,F.A.Inhibition by prostaglandins of leukotriene b4 release from activated neutrophils.Proc Natl Acad Sci USA 1983;80:4349-4353.
50.Standiford TJ,Kunkel,S.L,Rolfe,M.W.,Evanoff,H.L,Allen,R.M.and Strieter,R. M.w.Regulation of human alveolar macrophage-and blood monocytederived interleukin-8 by prostaglandin e2 and dexamethasone..Am J Respir Cell Mol Biol 1992;6:75-81.
51.Shinomiya S,Naraba,H.,Ueno,A.et al.Regulation of tnfa and interleukin-10 production by prostaglandins i2 and e2:Studies with prostaglandin receptor-deficient mice and prostaglandin e-receptor subtype-selective synthetic agonists.Biochem Pharmacol 2001;61:1153-1160.
52.Strassmann G,Patil-Koota,V.,Finkelman,R,Fong,M.and Kambayashi,T..Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin e2..J Exp Med 1994;180:2365-2370.
53.Los M,Schenk,H.,Hexel,K.,Baeuerle,P.A.,Droge,W.and Schulze-Osthoff,K.II-2 gene expression and nf-Kb activation through cd28 requires reactive oxygen production by 5 lipoxygenase.EMBO J 1995;14:3731-3740.
54.Mensing HaC,B.M.Leukotriene b4 induces in vitro fibroblast chemotaxis.J Invest Dermatol 1984;82:9-12.
55.Fireman E,Schwartz,Y.,Mann,A.and Greif,J.Effect of montelukast,a cysteinyl receptor antagonist,on myofibroblasts in interstitial lung disease..J Clin Immunol 2004;24:418-425.
56.Kohyama T,Ertl,R.F.,Valenti,V.et al..Prostaglandin e2 inhibits fibroblast chemotaxis.Am J Physiol 2001;281:L1257-L1263.
57.M.MBaP-G Prostaglandin e(2) inhibits fibroblast migration by e-prostanoid 2 receptor-mediated increase in pten activity.Am J Respir Cell Mol Biol 2005;32:135-141.
58.Goldstein RH,Sakowski,S.,Meeker,D.,Franzblau,C.and Polgar,P..The effect of prostaglandin e2(pge2) on amino acid uptake and protein formation by lung fibroblasts..J Biol Chem 1986;261:8734-8737.
59.Boyle JE,Lindroos,P.M.,Rice,A.B.,Zhang,L.,Zeldin,D.C.and Bonner,J.C.Prostaglandin-e2 counteracts interleukin-1β-stimulated upregulation of platelet-derived growth factor a-receptor on rat pulmonary myofibroblasts..Am J Respir Cell Mol Biol 1999;20:433-440.
60.Kolodsick JE,Peters-Golden M,Larios J,Toews GB,Thannickal VJ,Moore BB.Prostaglandin e2 inhibits fibroblast to myofibroblast transition via e.Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.Am J Respir Cell Mol Biol,2003;29:537-544.
61.Goldstein RHaP,P..The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts.J Biol Chem 1982;257:8630-8633.
62.Baum BJ,Moss,J.,Breul,S.D.,Berg,R.A.and Crystal.R.G.Effect of cyclic amp on the intracellular degradation of newly synthesized collagen..J Biol Chem 1980;255:2843-2847.
63.Clark JG,Kostal KM,Marino BA.Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters.Presence of a factor in lung that increases fibroblast prostaglandin e2 and camp and suppresses fibroblast proliferation and collagen production.J Biol Chem 1982;257:8098-8105.
64.Borok Z,Gillissen A,Buhl R,Hoyt RF,Hubbard RC,Ozaki T,Rennard SI,Crystal RG Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
65.Wilborn J,Crofford LJ,Burdick MD,Kunkel SL,Strieter RM,Peters-Golden M.Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin e2 and to express cyclooxygenase-2.J Clin Invest 1995;95:1861-1868.
66.Vancheri C,Sortino MA,Tomaselli V,Mastruzzo C,Condorelli F,Bellistri G,Pistorio MP,Canonico PL,Crimi N.Different expression of tnf-alpha receptors and prostaglandin e(2)production in normal and fibrotic lung fibroblasts:Potential implications for the evolution of the inflammatory process.Am J Respir Cell Mol Biol 2000;22:628-634.
67.CB K,RG J,NK H,NA H-R,H B,GJ L,SL H,ML F,RJ.M.Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.Am J Pathol 2001;158:1411-1422.
68.Huang S,Wettlaufer SH,C.Hogaboam DMA,Peters-Golden M,February 1 L-L.Prostaglandin e2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via e prostanoid 2 receptor and camp signaling.Am J Physiol Lung Cell Mol Physiol,2007;292:L405-413.
69.R.J.Hodges RGJ,C.P.D.Wheeler-Jones,D.M.Copeman,S.E.Bottoms,G J.Bellingan,C.B.Nanthakumar,G J.Laurent,S.L.Hart,M.L.Foster,et al.Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin e2 production.Am J Pathol 2004;165:1663-1676.
70.Ogushi F,Endo T,Tani K,Asada K,Kawano T,Tada H,Maniwa K,Sone S.Decreased prostaglandin e2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis.Int J Exp Pathol 1999;80:41-49.
71.Kohyama T,Ertl RF,Valenti V,Spurzem J,Kawamoto M,Nakamura Y,Veys T,Allegra L,Romberger D,Rennard SI.Prostaglandin e(2) inhibits fibroblast chemotaxis.Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-1263.
72.Vibha Lama BBM,Paul Christensen,Galen B.Toews,and Marc Peters-Golden Prostaglandin e2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.Am J Respir Cell Mol Biol 2002;27.
73.Failla M,Genovese T,Mazzon E,Fruciano M,Fagone E,Gili E,Barera A,La Rosa C,Conte E,Crimi N,et al.16,16-dimethyl prostaglandin e2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis.Am J Respir Cell Mol Biol 2008.
74.Charbeneau RP,Christensen PJ,Chrisman CJ,Paine R,3rd,Toews GB,Peters-Golden M,Moore BB.Impaired synthesis of prostaglandin e2 by lung fibroblasts and alveolar epithelial cells from gm-csf-/-mice:Implications for fibroproliferation.Am J Physiol Lung Cell Mol Physiol 2003;284:L1103-1111.
75.Moore BB P-GM,Christensen PJ,Lama V,Kuziel WA,Paine R III,and Toews GB..Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by mcp-1/ccr2 and mediated by pge2..Am J Physiol Lung Cell Mol Physiol 2003;284:L342-L349.
76.M Molina-Molina AS-M,O Bulbena,L Femandez-Zabalegui,D Closa,A Marin-Arguedas,A Torrego,J Mullol,C Picado,and A Xaubet.Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin e2 synthesis.Thorax 2006;61:604-610.
77.Kern Lovgren A JL,Hartney JM,Parsons KK,Audoly LP,FitzGerald GA,Tilley SL,and Koller BH.Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis..Am J Physiol Lung Cell Mol Physiol 2006;291:L144-L156.
78.Koichiro Kamio XL,Hisatoshi Sugiura,Shinsaku Togo,Tetsu Kobayashi,Shinsaku Kawasaki,Xingqi Wang,Lijun Mao,Youngsoo Ahn,Cory Hogaboam,Myron L.Toews,and Stephen I.Rennard Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the camp-pka pathway.Am J Respir Cell Mol Biol 2007;37.
79.Murakami S NN,Itoh T,Kataoka M,lwase T,Horio T,Miyahara Y,Sakai Y,Kangawa K,Kimura H.Prostacyclin agonist with thromboxane synthase inhibitory activity(ono-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.Am J Physiol Lung Cell Mol Physiol 2006;290:L59-65.
80.Ferhana Y.Ali KE,Garret A.FitzGerald,Beatrice Desvergne,Walter Wahli,David Bishop-Bailey,Timothy D.Warner,and Jane A.Mitchell Role of prostacyclin versus peroxisome proliferator-activated receptor receptors in prostacyclin sensing by lung fibroblasts.Am J Respir Cell Mol Biol 2005;34:242-246.
81.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates coilagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
82.Peters-Golden M,Bailie M,Marshall T,Wilke C,Phan SH,Toews GB,Moore BB.Protection from pulmonary fibrosis in leukotriene-deficient mice.Am J Respir Crit Care Med 2002;165:229-235.
83.Beller TC,Friend DS,Maekawa A,Lam BK,Austen KF,Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.Proc Natl Acad Sci U S A 2004;101:3047-3052.
84.Brock TG,Lee YJ,Maydanski E,Marburger TL,Luo M,Paine R,3rd,Peters-Golden M.Nuclear localization of leukotriene a4 hydrolase in type ii alveolar epithelial cells in normal and fibrotic lung.Am J Physiol Lung Cell Mol Physiol 2005;289:L224-232.
85.Izumo T,Kondo M,Nagai A.Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.Life Sci 2007;80:1882-1886.
86.Genovese T,Cuzzocrea S,Di Paola R,Mazzon E,Mastruzzo C,Catalano P,Sortino M,Crimi N,Caputi AP,Thiemermann C,et al.Effect of rosiglitazone and 15-deoxy-delta12,14-prostaglandin j2 on bleomycin-induced lung injury.Eur Respir J 2005;25:225-234.
87.Cruz-Gervis R,Stecenko AA,Dworski R,Lane KB,Loyd JE,Pierson R,King G,Brigham KL.Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis.Respir Res 2002;3:17.
2.Taylor DA,du Bois RM.Idiopathic interstitial pneumonias:A re-appraisal of idiopathic pulmonary fibrosis.Int J Tuberc Lung Dis 2001;5:1086-1098.
3.Michaelson JE,Aguayo SM,Roman J.Idiopathic pulmonary fibrosis:A practical approach for diagnosis and management.Chest 2000;118:788-794.
4.Nagai S,Kitaichi M,Hamada K,Nagao T,Hoshino Y,Miki H,Izumi T.Hospital-based historical cohort study of 234 histologically proven Japanese patients with ipf.Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-214.
5.Selman M,King TE,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
6.Raghu G,Weycker D,Edelsberg J,Bradford WZ,Oster G Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2006;174:810-816.
7.Noble PW.Idiopathic pulmonary fibrosis:Natural history and prognosis.Clin Chest Med 2006;27:S11-16,v.
8.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
9.Vasakova M,Striz I,Slavcev A,Jandova S,Dutka J,Terl M,Kolesar L,Sulc J.Correlation of il-1 alpha and il-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis.Scand J Immunol 2007;65:265-270.
10.Ziora D.[serum biomarkers in idiopathic pulmonary fibrosis].Pneumonol Alergol Pol 2007;75:268-272.
11.Tsoutsou PG,Gourgoulianis Kl,Petinaki E,Germenis A,Tsoutsou AG Mpaka M,Efremidou S,Molyvdas PA.Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis.Respir Med 2006;100:938-945.
12.Vasakova M,Striz I,Slavcev A,Jandova S,Kolesar L,Sulc J.Th1/th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis.Tissue Antigens 2006;67:229-232.
13.Millar AB.11-10:Another therapeutic target in idiopathic pulmonary fibrosis?Thorax 2006;61:835-836.
14.Uhal BD,Kim JK,Li X,Molina-Molina M.Angiotensin-tgf-beta 1 crosstalk in human idiopathic pulmonary fibrosis:Autocrine mechanisms in myofibroblasts and macrophages.Curr Pharm Des 2007;13:1247-1256.
15.Tzortzaki EG,Antoniou KM,Zervou Ml,Lambiri I,Koutsopoulos A,Tzanakis N,Plataki M,Maltezakis G Bouros D,Siafakas NM.Effects of antifibrotic agents on tgf-beta1,ctgf and ifn-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med 2007;101:1821-1829.
16.Pilewski JM,Liu L,Henry AC,Knauer AV,Feghali-Bostwick CA.Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition.Am J Pathol 2005;166:399-407.
17.Pierce EM,Carpenter K,Jakubzick C,Kunkel SL,Evanoff H,Flaherty KR,Martinez FJ,Toews GB,Hogaboam CM.Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to cc chemokine ligand 21.Eur Respir J 2007;29:1082-1093.
18.Nakayama S,Mukae H,Ishii H,Kakugawa T,Sugiyama K,Sakamoto N,Fujii T,Kadota J,Kohno S.Comparison of balf concentrations of ena-78 and ip10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.Respir Med 2005;99:1145-1151.
19.Papiris SA,Kollintza A,Karatza M,Manali ED,Sotiropoulou C,Milic-Emili J,Roussos C,Daniil Z.Cd8+ t lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis.J Inflamm(Lond) 2007;4:14.
20.Murata K,Ota S,Niki T,Goto A,Li CP,Ruriko UM,Ishikawa S,Aburatani H,Kuriyama T,Fukayama M.P63-key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis.Exp Mol Pathol 2007;83:367-376.
21.Feghali-Bostwick CA,Tsai CG,Valentine VG Kantrow S,Stoner MW,Pilewski JM,Gadgil A,George MP,Gibson KF,Choi AM,et al.Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis.J Immunol 2007;179:2592-2599.
22.Selman M,Pardo A.Role of epithelial cells in idiopathic pulmonary fibrosis:From innocent targets to serial killers.Proc Am Thorac Soc 2006;3:364-372.
23.Myers JL,Selman M.Respiratory epithelium in usual interstitial pneumonia/idiopathic pulmonary fibrosis:Spark or destructive flame?Am J Respir Crit Care Med 2004;169:3-5.
24.Selman M,Pardo A.The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis.Am J Respir Cell Mol Biol 2003;29:S93-97.
25.Moodley YP,Scaffidi AK,Misso NL,Keerthisingam C,McAnulty RJ,Laurent GJ,Mutsaers SE,Thompson PJ,Knight DA.Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.Am J Pathol 2003;163:345-354.
26.Nadrous HF,Ryu JH,Douglas WW,Decker PA,Olson EJ.Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis.Chest 2004;126:438-446.
27.Strieter RM,Starko KM,Enelow Rl,Noth I,Valentine VG Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;170:133-140.
28.O'Connor TM,Bredin CP.Interferon-gamma toxicity in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;169:428.
29.Gharaee-Kermani M,Hu B,Phan SH,Gyetko MR.Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis:Focus on tgfbeta signaling and the myofibroblast.Curr Med Chem 2009;16:1400-1417.
30.Raghu G,Brown KK,Bradford WZ,Starko K,Noble PW,Schwartz DA,King TE,Jr.A placebo-controlled trial of interferon gamma-1 b in patients with idiopathic pulmonary fibrosis.N Engl J Med 2004;350:125-133.
31.Selman M,Thannickal VJ,Pardo A,Zisman DA,Martinez FJ,Lynch JP,3rd.Idiopathic pulmonary fibrosis:Pathogenesis and therapeutic approaches.Drugs 2004;64:405-430.
32.Clark JG,Kostal KM,Marino BA.Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters.Presence of a factor in lung that increases fibroblast prostaglandin e2 and camp and suppresses fibroblast proliferation and collagen production.J Biol Chem 1982;257:8098-8105.
33.Clark JG,Kostal KM,Marino BA.Bleomycin-induced pulmonary fibrosis in hamsters.An alveolar macrophage product increases fibroblast prostaglandin e2 and cyclic adenosine monophosphate and suppresses fibroblast proliferation and collagen production.J Clin Invest 1983,72:2082-2091.
34.Ogushi F,Endo T,Tani K,Asada K,Kawano T,Tada H,Maniwa K,Sone S.Decreased prostaglandin e2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis.Int J Exp Pathol 1999;80:41-49.
35.Jenkins G,Hart SL,Hodges RJ,Meng QH,Kinnon C,Laurent GJ,McAnulty RJ.Cyclooxygenase-2 overexpression,using an integrin-targeted gene delivery system(the lid vector),inhibits fibroblast proliferation in vitro and leads to increased prostaglandin e(2) in the lung.Chesf 2002;121:102S-104S.
36.Phan SH,McGarry BM,Loeffler KM,Kunkel SL.Binding of leukotriene c4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro.Biochemistry 1988;27:2846-2853.
37.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates collagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
38.Charbeneau RP P-GM.Eicosanoids:Mediators and therapeutic targets in fibrotic lung disease.Clin Sci(Lond) 2005;108:479-491.
39.Borok Z GA,Buhl R,et al.Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
40.Wilbom J,Crofford LJ,Burdick MD,Kunkel SL,Strieter RM,Peters-Golden M.Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin e2 and to express cyclooxygenase-2.J Clin Invest 1995;95:1861-1868.
41.Keerthisingam CB JR,Harrison NK.Hemandez-Rodriguez NA.Booth H.Laurent GJ,Hart SL,Foster ML,McAnulty RJ.Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.Am J Pathol 2001;158:1411-1422.
42.Vancheri C SM,Tomaselli V,et al.Different expression of tnf-alpha receptors and prostaglandin e(2) production in normal and fibrotic lung fibroblasts:Potential implications for the evolution of the inflammatory process.Am J Respir Cell Mol Biol 2000;22:628-634.
43.Huang S,Wettlaufer SH,C.Hogaboam DMA,Peters-Golden M,February 1 L-L. Prostaglandin e2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via e prostanoid 2 receptor and camp signaling.Am J Physiol Lung Cell Mol Physiol,2007;292:L405-413.
44.R.J.Hodges RGJ,C.P.D.Wheeler-Jones,D.M.Copeman,S.E.Bottoms,G J.Bellingan,C.B.Nanthakumar,G J.Laurent,S.L.Hart,M.L.Foster,et al.Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin e2 production.Am J Pathol 2004;165:1663-1676.
45.Kohyama T,Ertl RF,Valenti V,Spurzem J,Kawamoto M,Nakamura Y,Veys T,Allegra L,Romberger D,Rennard SI.Prostaglandin e(2) inhibits fibroblast chemotaxis.Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-1263.
46.Vibha Lama BBM,Paul Christensen,Galen B.Toews,and Marc Peters-Golden Prostaglandin e2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.Am J Respir Cell Mol Biol 2002;27.
47.Kolodsick JE,Peters-Golden M,Larios J,Toews GB,Thannickal VJ,Moore BB.Prostaglandin e2 inhibits fibroblast to myofibroblast transition via e.Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.Am J Respir Cell Mol Biol 2003;29:537-544.
48.Zhang A,Wang MH,Dong Z,Yang T.Prostaglandin e2 is a potent inhibitor of epithelial-to-mesenchymal transition:Interaction with hepatocyte growth factor.Am J Physiol Renal Physiol 2006;291:F1323-1331.
49.Failla M GT,Mazzon E,Fruciano M,Fagone E,Gili E,Barera A,La Rosa C,Conte E,Crimi N,Cuzzocrea S,Vancheri C.16,16-dimethyl prostaglandin e2 efficacy on prevention and protection from bieomycin-induced lung injury and fibrosis.Am J Respir Cell Mol Biol 2008.
50.Cruz-Gervis R SA,Dworski R,Lane KB,Loyd JE,Pierson R,King G,Brigham K.Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis..Respir Res 2002;3:17.
51.Kern Lovgren A JL,Hartney JM,Parsons KK,Audoly LP,FitzGerald GA,Tilley SL,and Koller BH.Cox-2-derived prostacyclin protects against bieomycin-induced pulmonary fibrosis..Am J Physiol Lung Cell Mol Physiol 2006,291:L144-L156.
52.Koichiro Kamio XL,Hisatoshi Sugiura,Shinsaku Togo,Tetsu Kobayashi,Shinsaku Kawasaki,Xingqi Wang,Lijun Mao,Youngsoo Ahn,Cory Hogaboam,Myron L.Toews,and Stephen I.Rennard Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the camp-pka pathway.Am J Respir Cell Mol Biol 2007;37.
53.Ferhana Y.AN KE,Garret A.FitzGerald,Beatrice Desvergne,Walter Wahli,David Bishop-Bailey,Timothy D.Warner,and Jane A.Mitchell Role of prostacyclin versus peroxisome proliferator-activated receptor receptors in prostacyclin sensing by lung fibroblasts.Am J Respir Cell Mol Biol 2005;34:242-246.
54.Stratton R,Shiwen X,Martini G,Holmes A,Leask A,Haberberger T,Martin GR,Black CM,Abraham D.Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.J Clin Invest 2001;108:241-250.
55.Yu H,Gallagher AM,Garfin PM,Printz MP.Prostacyclin release by rat cardiac fibroblasts:Inhibition of collagen expression.Hypertension 1997;30:1047-1053.
56.Nana-Sinkam P,Lee JD,Sotto-Santiago S,Stearman RS,Keith RL,Choudhury Q, Cool C,Parr J,Moore MD,Bull TM,et al.Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.Am J Respir Crit Care Med 2007;175:676-685.
57.Idzko M HH,van Nimwegen M,Kool M,Vos N,Hoogsteden HC,Lambrecht BN.Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.J Clin Invest 2007;117:464-472.
58.Nagao K.ea.Role of prostaglandin i2 in airway remodeling induced by repeated allergen challenge in mice..Am J Respir Cell Mol Biol 2003;29:314-320.
59.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
60.Zardi EM,Dobrina A,Amoroso A,Afeltra A.Prostacyclin in liver disease:A potential therapeutic option.Expert Opin Biol Ther 2007;7:785-790.
61.Kaneshige T,Saida Y,Tanaka R,Soda A,Fukushima A,Ida N,Takenaka M,Yamane Y.Effect of long-term administration of a prostacyclin analogue(beraprost sodium) on myocardial fibrosis in dahl rats.J Vet Med Sci 2007;69:1271-1276.
62.Nasrallah R,Hebert RL.Prostacyclin signaling in the kidney:Implications for health and disease.Am J Physiol Renal Physiol 2005;289:F235-246.
63.Lovgren AK,Jania LA,Hartney JM,Parsons KK,Audoly LP,Fitzgerald GA,Tilley SL,Koller BH.Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis.Am J Physiol Lung Cell Mol Physiol 2006;291:L144-156.
64.Skuballa W,Raduchel,B.,and Vorbruggen,H.1985.Chemistry of stable prostacyclin analogues:synthesis of Iloprost.In Prostacyclin and its stable analogue Iloprost.R.G Gryglewski and G Stock,editors.Springer-Verlag.Berlin,Germany.17-24.
65.SK H,M P-G Eicosanoid lipid mediators in fibrotic lung diseases:Ready for prime time?Chet 2006;133:1442-1445.
66.Antoniou KM,Alexandrakis MG,Siafakas NM,Bouros D.Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis.Sarcoidosis Vase Diffuse Lung Dis 2005;22:91-104.
67.Christmas RJSaP.Revisiting prostacyclin:New directions in pulmonary fibrosis and inflammation Am J Physiol Lung Cell Mol Physiol 2006,291.L142-L143.
68.Hattori N DJ,Sisson TH,Liu H,Moore BB,Pandrangi RG,Simon RH,Drew AF.Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.J Clin Invest 1988;106:1341-1350.
69.Voltz JW,Card JW,Carey MA,DeGraff LM,Ferguson CD,Flake GP,Bonner JC,Korach KS,Zeldin DC.Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis.Am J Respir Cell Mol Biol 2008;39:45-52.
70.Nagase T,Uozumi N,Ishii S,Kita Y,Yamamoto H,Ohga E,Ouchi Y,Shimizu T.A pivotal role of cytosolic phospholipase a2 in bleomycin-induced pulmonary fibrosis.Nature Medicine 2002;8:480-484.
71.Waseda Y YM,Nishizawa Y,Inuzuka K,Takato H,Ichikawa Y,Tagami A,Fujimura M,Nakao S.Angiotensin ii type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.Respir Res 2008;9:43.
72.Moore BB BM,White ES,Green ME,Herrygers AB,Wilke CA,Toews GB,and Peters-Golden M..Bleomycin-induced e prostanoid receptor changes alter fibroblast responses to prostaglandin e2.J Immunol 2005;174:5644-5649.
73.James H HJaLJ.High dose continuous infusion of bleomycin in mice:A new model for drug-induced pulmonary fibrosis..J Pharmo Exp Thera 1987;243:1185-1194.
74.R.Dembinski WB,D.Henzler,A.Rott,R.Bensberg,R.Kuhlen,and R.Rossaint.Cardiopulmonary effects of iloprost in experimental acute lung injury.Eur Respir J 2005;25:81-87.
75.Ashcroft T SJ,Timbrell V.Simple method of estimating severity of pulmonary fibrosis on a numerical scale..J Clin Pathol 1988;41:467-470.
76.Beller TC FD,Maekawa A,Lam BK,Austen KF,and Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis..Proc Natl Acad Sci USA 2004;101:3047-3052.
1.Gallagher AM,Yu H,Printz MP.Bradykinin-induced reductions in collagen gene expression involve prostacyclin.Hypertension 1998;32:84-88.
2.Yu H,Gallagher AM,Garfin PM,Printz MP.Prostacyclin release by rat cardiac fibroblasts:Inhibition of collagen expression.Hypertension 1997;30:1047-1053.
3.Stratton R,Shiwen X,Martini G,Holmes A,Leask A,Haberberger T,Martin GR,Black CM,Abraham D.Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.J Clin Invest 2001;108:241-250.
4.RL.NRaHb.Reduced ip receptors in stz-induced diabetic rat kidneys and high-glucose-treated mesangial cells.Am J Physiol Renal Physiol 2004;287:F673-F681.
5.Stratton R,Rajkumar V,Ponticos M,Nichols B,Shiwen X,Black CM,Abraham DJ,Leask A.Prostacyclin derivatives prevent the fibrotic response to tgf-beta by inhibiting the ras/mek/erk pathway.FASEB J 2002;16:1949-1951.
6.Felix Chua JG and Geoffrey J.Laurent.Pulmonary fibrosis:Searching for model answers.Am J Respir Cell Mol Biol 2005;33:9-13.
7.Kaminski J AJ,Pittet F,Zuo F,Griffiths MJD,Morris D,Huang X,Sheppard D,Heller RA.Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis.Proc Natl Acad Sci USA 2000;97:1778-1783.
8.Saito F TS,Inoue K,Miyamoto K,Nakano Y,Ogawa Y,Yamada W,Shiraishi Y,Hasegawa N,Fujishima S,Takano H,Ishizaka A.Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice.Am J Respir Cell Mol Biol 2008;38:566-571.
9.Moodley YP,Scaffidi AK,Misso NL,Keerthisingam C,McAnulty RJ,Laurent GJ,Mutsaers SE,Thompson PJ,Knight DA.Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.Am J Pathol 2003;163:345-354.
10.Kim JH,Kim HY,Kim S,Chung JH,Park WS,Chung DH.Natural killer t(nkt) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.Am J Pathol 2005;167:1231-1241.
11.Baran CP OJ,McMaken S,Newland CA,O'Brien JM Jr,Hunter MG Bringardner BD,Monick MM,Brigstock DR,Stromberg PC,Hunninghake GW,Marsh CB.Important roles for m-csf,ccl2 and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis.Am J Respir Crit Care Med 2007;176:78-89.
12.B.B.Moore MP-G P.J-Christensen,V.Lama,W.A.Kuziel,R.Paine III,and G B.Toews.Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by mcp-1/ccr2 and mediated by pge2.Am J Physiol Lung Cell Mol Physiol 2003;284:L342-L349.
13.Wasmuth HE,Lammert F,Zaldivar MM,Weiskirchen R,Hellerbrand C,Scholten D,Berres ML,Zimmermann H,Streetz KL,Tacke F,et al.Anti-fibrotic effects of cxcl9 and its receptor cxcr3 in livers of mice and humans.Gastroenterology 2009.
14.Jiang D,Liang J,Hodge J,Lu B,Zhu Z,Yu S,Fan J,Gao Y,Yin Z,Homer R,et al. Regulation of pulmonary fibrosis by chemokine receptor cxcr3.J Clin Invest 2004;114:291-299.
15.Tager AM,Kradin RL,LaCamera P,Bercury SD,Campanella GS,Leary CP,Polosukhin V,Zhao LH,Sakamoto H,Blackwell TS,et al.Inhibition of pulmonary fibrosis by the chemokine ip-10/cxcl10.Am J Respir Cell Mol Biol 2004;31:395-404.
16.Nakayama S,Mukae H,Ishii H,Kakugawa T,Sugiyama K,Sakamoto N,Fujii T,Kadota J,Kohno S.Comparison of balf concentrations of ena-78 and ip10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.Respir Med 2005;99:1145-1151.
17.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
18.Christmas RJSaP.Revisiting prostacyclin:New directions in pulmonary fibrosis and inflammation Am J Physiol Lung Cell Mol Physiol 2006;291:L142-L143.
19.Society.ATSER.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med 2002;165:227-304.
20.Huang M sS,Zhu LX,Keane MP,Luo.J,Zhang L,et al.Ⅱ-7 inhibits fibroblast tgf-beta production and signaling in pulmonary fibrosis.J Clin Invest 2002;109:931-937.
21.Nakao A FM,Matsumura R,Kumano K,Saito Y,Miyazono K,et al.Transient gene transsfer and expression of smad 7 prevents bleomycin-induced lung fibrosis in mice.J Clin Invest 1999;104:5-11.
22.Raghu G JW,Lockhart D,Mageto Y Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:Results of a prospective,open-label phase ii study.Am J Respir Crit Care Med 1999;159:1061-1069.
23.Piguet PF VC.Treatment by human recombinant soluble tnf receptor of pulmonary fibrosis induced by bleomycin or silica in mice.Eur Respir J 1994;7:515-518.
24.Sime PJ ORK.Fibrosis of the lung and other tissues:New concepts in pathogenesis and treatment.Clin Immunol 2001;99::308-319.
25.Molina-Molina M,Serrano-Mollar A,Bulbena O,Femandez-Zabalegui L,Closa D,Marin-Arguedas A,Torrego A,Mullol J,Picado C,Xaubet A,et al.Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin e2 synthesis.Thorax 2006;61:604-610.
26.Nogee LM DAI,Wert SE,Askin F,Hamas A,Whitsett JA..A mutation in the surfactant c protein associated with familial interstitial lung disease.N Engl J Med 2001;344:573-579.
27.Thomas AO LK,Phillips J III,Markin PM,Speer M,Schwartz DA,Gaddipati R,Marvnev A,Johnson J,Roberts R,et al..Heterozygosity for a surfactant protein c mutation associated with usual interstitial pneumonia and cellular non-specific interstitial pneumonia in one kindred.Am J Respir Crit Care Med 2002;165:1322-1328.
28.Marney A,Lane KB,Phillips JA,3rd,Riley DJ,Loyd JE.Idiopathic pulmonary fibrosis can be an autosomal dominant trait in some families.Chest 2001;120:56S.
29.Stewart JP EJ,Ross AJ,et al..The detection of epstein-barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis..Am J Respir Crit Care Med 1999;159:1336-1341.
30.Yi-Wei Tang JEJ,Philip J.Browning,Roberto A.Cruz-Gervis,Angela Davis,Barney S.raham.Kenneth L.Brigham,John A.Oates Jr.,James E.Loyd,and Arlene A.Stecenko.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.JOURNAL OF CLINICAL MICROBIOLOGY 2003;June 2633-2640.
31.Gauldie J,Kolb M,Sime PJ.A new direction in the pathogenesis of idiopathic pulmonary fibrosis?Respir Res 2002;3:1.
32.Pardo A,Selman M.Idiopathic pulmonary fibrosis:New insights in its pathogenesis.Int J Biochem Cell Biol 2002;34:1534-1538.
33.Lok SS,Egan JJ.Viruses and idiopathic pulmonary fibrosis.Monaldi Arch Chest Dis 2000;55:146-150.
34.Tang YW,Johnson J,Cruz-Gervis R,Graham B,Brigham K,Oates J,Loyd J,Stecenko A.Increased detection of herpesvirus DNA in idiopathic pulmonary fibrosis.Chest 2001;120:74S-75S.
35.Lok SS,Stewart JP,Kelly BG,Hasleton PS,Egan JJ.Epstein-barr virus and wild p53 in idiopathic pulmonary fibrosis.Respir Med 2001;95:787-791.
36.Kelly BG,Lok SS,Hasleton PS,Egan JJ,Stewart JP.A rearranged form of epstein-barr virus DNA is associated with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2002;166:510-513.
37.Tang YW,Johnson JE,Browning PJ,Cruz-Gervis RA,Davis A,Graham BS,Brigham KL,Oates JA,Jr.,Loyd JE,Stecenko AA.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.J Clin Microbiol 2003;41:2633-2640.
38.Flaherty KR TW,Colby TV,Toews GB,Kazerooni EA,Gross BH,Jain A,Strawderman RL,Flint A,Lynch JP,e.t al..Histopathologic variability in usual and nonspecific interstitial pneumonias..Am J Respir Crit Care Med 2001;164:1722-1727.
39.FJ.M.Idiopathic interstitial pneumonias:Usual interstitial pneumonia versus nonspecific interstitial pneumonia.Proc Am Thorac Soc 2006;3:81-95.
40.Ando M,Miyazaki E,Fukami T,Kumamoto T,Tsuda T.lnterleukin-4-producing cells in idiopathic pulmonary fibrosis:An immunohistochemical study.Respirology 1999;4:383-391.
41.Lemjabbar H,Gosset P,Lechapt-Zalcman E,Franco-Montoya ML,Wallaert B,Harf A,Lafuma C.Overexpression of alveolar macrophage gelatinase b(mmp-9) in patients with idiopathic pulmonary fibrosis:Effects of steroid and immunosuppressive treatment.Am J Respir Cell Mol Biol 1999;20:903-913.
42.Liu L,Zong Z,Li Z.[changes on the protein kinase c activity of alveolar macrophages in patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2000;23:397-399.
43.Ogushi F,Tani K,Endo T,Tada H,Kawano T,Asano T,Huang L,Ohmoto Y,Muraguchi M,Moriguchi H,et al.Autoantibodies to il-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis.J Med Invest 2001;48:181-189.
44.Pantelidis P,Fanning GC,Wells AU,Welsh Kl,Du Bois RM.Analysis of tumor necrosis factor-alpha,lymphotoxin-alpha,tumor necrosis factor receptor ii,and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2001;163:1432-1436.
45.Xiao L,Li ZH,Hou XM,Yu RJ.[evaluation of interleukin-13 in the serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2003;26:686-688.
46.Zorzetto M,Ferrarotti I,Trisolini R,Agli LL,Scabini R,Novo M,De Silvestri A,Patelli M,Martinetti M,Cuccia M,et al.Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2003;168:330-334.
47.Kitasato Y,Hoshino T,Okamoto M,Kato S,Koda Y,Nagata N,Kinoshita M,Koga H,Yoon DY,Asao H,et al.Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis.Am J Respir Cell Mol Biol 2004;31:619-625.
48.Collard HR MB,Flaherty KR,Brown KK,Kaner RJ,King TE Jr,Lasky JA,Loyd JE,Noth I,Olman MA,Raghu G,Roman J,Ryu JH,Zisman DA,Hunninghake GW,Colby TV,Egan JJ,Hansell DM,Johkoh T,Kaminski N,Kim DS,Kondoh Y,Lynch DA,Muller-Quernheim J,Myers JL,Nicholson AG,Selman M,Toews GB,Wells AU,Martinez FJ;Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators.Acute exacerbations of idiopathic pulmonary fibrosis-Am J Respir Crit Care Med 2007;176:636-643.
49.Dallari R,Foglia M,Paci M,Cavazza A.Acute exacerbation of idiopathic pulmonary fibrosis.Eur Respir J 2004;23:792.
50.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
51.Kohyama T LX,Kim HJ,Kobayashi T,Ertl RF,Wen FQ,Takizawa H,and Rennard
51.Prostacyclin analogs inhibit fibroblast migration..Am J Physiol Lung Cell Mol Physiol 2002;283:L428-L432.
52.Nana-Sinkam P,Lee JD,Sotto-Santiago S,Stearman RS,Keith RL,Choudhury Q,Cool C,Parr J,Moore MD,Bull TM,et al.Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.Am J Respir Crit Care Med 2007;175:676-685.
53.Jaffar Z.WKS,Roberts K.A key role for prostaglandin i2 in limiting lung mucosal th2,but not th1,responses to inhaled allergen..J Immunol 2002;169:5997-6004.
54.Nagao K.ea.Role of prostaglandin i2 in airway remodeling induced by repeated allergen challenge in mice..Am J Respir Cell Mol Biol 2003;29:314-320.
55.Chaudhary Nl,Schnapp A,Park JE.Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.Am J Respir Crit Care Med 2006;173:769-776.
56.J.W.Card JWV,M.A.Carey,J.A.Bradbury,L.M.DeGraff,F.B.Lih,J.C.Bonner,D.L.Morgan,G P.Flake,and D.C.Zeldin.Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.Am J Respir Cell Mol Biol 2007;37:300-308.
57.Fujita M YQ,Ouchi H,Harada E,Inoshima I,Kuwano K,Nakanishi Y.Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice.Antimicrob Agents Chemother 2006;50:739-743.
58.Keane MP BJ,Arenberg DA,Burdick MD,Xu ZJ,Xue YY,Strieter RM.Ifn-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.J Immunol 1999;176:7087-7095.
59.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.This joint statement of the american thoracic society(ats),and the european respiratory society(ers) was adopted by the ats board of directors,June 2001 and by the ers executive committee,June 2001.Am J Respir Crit Care Med 2002;165:277-304.
60.Murray LA,Argentieri RL,Farrell FX,Bracht M,Sheng H,Whitaker B,Beck H,Tsui P,Cochlin K,Evanoff HL,et al.Hyper-responsiveness of ipf/uip fibroblasts:Interplay between tgfbetal,il-13 and ccl2.Int J Biochem Cell Biol 2008;40:2174-2182.
61.Uhal BD,Kim JK,Li X,Molina-Molina M.Angiotensin-tgf-beta 1 crosstalk in human idiopathic pulmonary fibrosis:Autocrine mechanisms in myofibroblasts and macrophages.Curr Pharm Des 2007;13:1247-1256.
62.Tzortzaki EG,Antoniou KM,Zervou Ml,Lambiri I,Koutsopoulos A,Tzanakis N,Plataki M,Maltezakis G,Bouros D,Siafakas NM.Effects of antifibrotic agents on tgf-beta1,ctgf and ifn-gamma expression in patients with idiopathic pulmonary fibrosis.Respir Med 2007;101:1821-1829.
63.Bergeron A,Soler P,Kambouchner M,Loiseau P,Milleron B,Valeyre D,Hance AJ,Tazi A.Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for tgf-beta and il-10.Eur Respir J 2003;22:69-76.
64.Gharaee-Kermani M,Hu B,Phan SH,Gyetko MR.Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis:Focus on tgfbeta signaling and the myofibroblast.Curr Med Chem 2009;16:1400-1417.
65.Zhang K,Gharaee-Kermani M,McGarry B,Remick D,Phan SH.Tnf-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis.J Immunol 1997;158:954-959.
66.Piguet PF,Vesin C.Treatment by human recombinant soluble tnf receptor of pulmonary fibrosis induced by bleomycin or silica in mice.Eur Respir J 1994;7:515-518.
67.Ask K,Bonniaud P,Maass K,Eickelberg O,Margetts PJ,Warburton D,Groffen J,Gauldie J,Kolb M.Progressive pulmonary fibrosis is mediated by tgf-beta isoform 1 but not tgf-beta3.Int J Biochem Cell Biol 2008;40:484-495.
68.Bonniaud P,Kolb M,Gait T,Robertson J,Robbins C,Stampfli M,Lavery C,Margetts PJ,Roberts AB,Gauldie J.Smad3 null mice develop airspace enlargement and are resistant to tgf-beta-mediated pulmonary fibrosis.J Immunol 2004;173:2099-2108.
69.Branton MH,Kopp JB.Tgf-beta and fibrosis.Microbes Infect 1999;1:1349-1365.
70.McCormick LL,Zhang Y,Tootell E,Gilliam AC.Anti-tgf-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease:A model for human scleroderma.J Immunol 1999;163:5693-5699.
71.Kolb M,Margetts PJ,Gait T,Sime P,Xing Z,Schmid M.Transient transgene expression of decorin in thr lung reduces the fibrotic response to bleomycin.Am J Respir Crit Care Med 2001;163:770-777.
72.Wang Q,Wang Y,Hyde D,Gotwals P,Koteliansky V,Ryan ST.Reduction of bleomycin dnduced lung fibrosis by transformaing growth factor beta soluble receptor in hamster.Thorax 1999;54:805-812.
73.Lyer S,Gurujeyalakshmi G,Giri SN.Effects of pirfinidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther 1999;291:367-373.
74.Strieter R,Starko K,Enelow R,Noth I,Valentine V,Group IPFBS.Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2004;170:133-140.
75.Raghu G,Brown KK,Bradford WZ,Starko K,Noble PW,Schwartz DA,King TE,Jr.A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.N Engl J Med 2004;350:125-133.
76.Antoniou KM,Nicholson AG Dimadi M,Malagari K,Latsi P,Rapti A,Tzanakis N,Trigidou R,Polychronopoulos V,Bouros D.Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis.Eur Respir J 2006;28:496-504.
77.Gurujeyalakshmi G,Giri SN.Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis:Downregulation of tgf-beta and procollagen i and iii gene expression.Exp Lung Res 1995;21:791-808.
78.Ziesche R,Block LH.Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis.Wien Klin Wochenschr 2000;112:785-790.
79.Keane MP,Arenberg DA,Lynch JP,3rd,Whyte Rl,lannettoni MD,Burdick MD,Wilke CA,Morris SB,Glass MC,DiGiovine B,et al.The cxc chemokines,il-8 and ip-10,regulate angiogenic activity in idiopathic pulmonary fibrosis.J Immunol 1997;159:1437-1443.
80.Car BD,Meloni F,Luisetti M,Semenzato G,Gialdroni-Grassi G,Walz A.Elevated il-8 and mcp-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.Am J Respir Crit Care Med 1994;149:655-659.
81.Nakaya I,Wada T,Furuichi K,Sakai N,Kitagawa K,Yokoyama H,Ishida Y,Kondo T,Sugaya T,Kawachi H,et al.Blockade of ip-10/cxcr3 promotes progressive renal fibrosis.Nephron Exp Nephrol 2007;107:e12-21.
82.Tager AM KR,LaCamera P,Bercury SD,Campanella GS,Leary CP,Polosukhin V,Zhao LH,Sakamoto H,BIackwell TS,Luster AD.Inhibition of pulmonary fibrosis by the chemokine ip-10/cxcl10.Am J Respir Cell Mol Biol 2004;31:395-404.
83.Burdick MD ML,Keane MP,Xue YY,Zisman DA,Belperio JA,Strieter RM.Cxcl11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.Am J Respir Crit Care Med 2005;171:261-268.
84.Selman M,King TE,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
85.Antoniou KM,Tzanakis N,Tzortzaki EG Malagari K,Koutsopoulos AV,Alexandrakis M,Wells AU,Siafakas NM.Different angiogenic cxc chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients.Pulm Pharmacol Ther 2008;21:840-844.
86.MP K,JA B,TA M,BB M,DAA,RE S,MD B,SL K,RM S.Neutralization of the cxc chemokine,macrophage inflammatory protein-2,attenuates bleomycin-induced pulmonary fibrosis.J Immunol 1999;162:5511-5518.
87.Jiang D LJ,Hodge J,Lu B,Zhu Z,Yu S,Fan J,Gao Y,Yin Z,Homer R,Gerard C,Noble PW.Regulation of pulmonary fibrosis by chemokine receptor cxcr3.J Clin Invest 2004;114:291-299.
88.P P,G B,D M,MR Y,M F,B B,A B,G C,Nava S,G M.Role of the chemokine receptors cxcr3 and ccr4 in human pulmonary fibrosis.Am J Respir Crit Care Med 2006;173:310-317.
89.Capelli A,Di Stefano A,Gnemmi I,Donner CF.Ccr5 expression and cc chemokine levels in idiopathic pulmonary fibrosis.Eur Respir J 2005;25:701-707.
90.JH K,HY K,S K,JH C,WS P,DH C.Natural killer t(nkt) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.Am J Pathol 2005;167:1231-1241.
91.Izumo T,Kondo M,Nagai A.Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.Life Sci 2007,80:1882-1886.
92.Beller TC,Friend DS,Maekawa A,Lam BK,Austen KF,Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.Proc Natl Acad Sci U S A 2004;101:3047-3052.
93.Kowal-Bielecka O,Distler O,Kowal K,Siergiejko Z,Chwiecko J,Sulik A,Gay RE,Lukaszyk AB,Gay S,Sierakowski S.Elevated levels of leukotriene b4 and leukotriene e4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.Arthritis Rheum 2003;48:1639-1646.
94.Peters-Golden M,Bailie M,Marshall T,Wilke C,Phan SH,Toews GB,Moore BB.Protection from pulmonary fibrosis in leukotriene-deficient mice.Am J Respir Crit Care Med 2002;165:229-235.
95.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates collagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
96.Fujita M,Shannon JM,Morikawa O,Gauldie J,Hara N,Mason RJ.Overexpression of tumor necrosis factor-{alpha} diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-{beta}.Am J Respir Cell Mol Biol 2003;29:669-676.
97.Borok Z GA,Buhl R,et al.Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
98.Li JZ,Li ZH,Kang J,Hou XM,Yu RJ.[change of prostaglandin e2 and interleukin-12,interleukin-13 in the bronchoalveolar lavage fluid and the serum of the patients with idiopathic pulmonary fibrosis].Zhonghua Jie He He Hu Xi Za Zhi 2004;27:378-380.
1.American thoracic society/european respiratory society.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med 2002;165:227-304.
2.Selman M KT,Pardo A.Idiopathic pulmonary fibrosis:Prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med 2001;134:136-151.
3.Taylor DA,du Bois RM.Idiopathic interstitial pneumonias:A re-appraisal of idiopathic pulmonary fibrosis.IntJTuberc Lung Dis 2001;5:1086-1098.
4.Michaelson JE,Aguayo SM,Roman J.Idiopathic pulmonary fibrosis:A practical approach for diagnosis and management.Chest 2000;118:788-794.
5.Nagai S,Kitaichi M,Hamada K,Nagao T,Hoshino Y,Miki H,Izumi T.Hospital-based historical cohort study of 234 histologically proven Japanese patients with ipf.Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-214.
6.Raghu G,Weycker D,Edelsberg J,Bradford WZ,Oster G Incidence and prevalence of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2006;174:810-816.
7.Noble PW.Idiopathic pulmonary fibrosis:Natural history and prognosis.Clin Chest Med 2006;27:S11-16,v.
8.Funk C.Prostaglandins and leukotrienes:Advances in eicosanoid biology.Science 2001;294:1871-1875.
9.Kaneshige T,Saida Y,Tanaka R,Soda A,Fukushima A,Ida N,Takenaka M,Yamane Y.Effect of long-term administration of a prostacyclin analogue(beraprost sodium) on myocardial fibrosis in dahl rats.J Vet Med Sci 2007;69:1271-1276.
10.Yokoyama C,Yabuki T,Shimonishi M,Wada M,Hatae T,Ohkawara S,Takeda J,Kinoshita T,Okabe M,Tanabe T.Prostacyclin-deficient mice develop ischemic renal disorders,including nephrosclerosis and renal infarction.Circulation 2002;106:2397-2403.
11.Zardi EM,Dobrina A,Amoroso A,Afeltra A.Prostacyclin in liver disease:A potential therapeutic option.Expert Opin Biol Ther 2007;7:785-790.
12.RP C,M.P-G Eicosanoids:Mediators and therapeutic targets in fibrotic lung disease.Clin Sci(Lond) 2005;108:479-491.
13.Bhattacharya M,Peri,K.G,Almazan,G et al.Nuclear localization of prostaglandin e2 receptors.Proc Natl Acad Sci U S A 1998;95:15792-15797.
14.Narumiya S,Sugimoto,Y.and Ushikubi,F.Prostanoid receptors:Structures,properties,and functions.Physiol Rev 1999;79:1193-1226.
15.Lynch KR,O'Neill,G.P.,Liu,Q.et al.(1999)(London) 399,.Characterization of the human cysteinyl leukotriene receptor..Nature 1999;399:789-793.
16.Heise CE,O'Dowd,B.R,Figueroa,D.J.et al.Characterization of the human cysteinyl leukotriene 2 receptor..J Biol Chem 2000;275:30531-30536.
17.Yokomizo T,Izumi,T.,Chang,K.,Takuwa,Y.and Shimizu,T.A g-protein-coupled receptor for leukotriene b4 that mediates chemotaxis.Nature(London) 1997;387:620-624.
18.Yokomizo T,Kato,K.,Terawaki,K.,Izumi,T.and Shimizu,T.A second leukotriene b4 receptor,blt2:A new therapeutic target in inflammation and immunological disorders..J Exp Med 2000;192:421-432.
19.Martin TR,Pistorese,B.P.,Chi,E.Y,Goodman,R.B.and Matthay,M.A.Effects of leukotriene b4 in the human lung:Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.J Clin /nvest 1989;84:1609-1619.
20.Laitinen LA,Laitinen,A.,Haahtela,T.,Vilkka,V.,Spur,B.W.and Lee,T.H.Leukotriene e4 and granulocytic infiltration into asthmatic airways..Lancet 1993;341:989-990.
21.Cyr MMaD,J.A.Systemic aspects of allergic disease:The role of the bone marrow.Curr Opin Immunol 2001;13:727-732.
22.Pasquaie DaC,G Lipoxygenase products regulate proliferation of granulocytemacrophage progenitors.Exp Hematol 1993;21:1361-1365.
23.Nagy L,Lee,T.H.,Goetzl,E.J.,Pickett,W.C.and Kay,A.B..Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products.Clin Exp Immunol 1982;47:541-547.
24.Pedersen KE,Bochner,B.S.and Undem,B.J.Cysteinyl leukotrienes induce p-selectin expression in human endothelial cells via a non-cyslt1 receptormediated mechanism.J Pharmacol Exp Ther 1997;281:655-662.
25.Hebert MJ,Takano,T.,Holthofer,H.and Brady,H.R.Sequential morphologic events during apoptosis of human neutrophils:Modulation by lipoxygenase-derived eicosanoids.J Immunol 1996;157:3105-3115.
26.Lee E,Robertson,T.,Smith,J.and Kilfeather,S..Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals.Am J Respir Crit Care Med 2000;161:1881-1886.
27.Kane GC,Pollice,M.,Kim,C.J.et al.A controlled trial of the effect of the 5-lipoxygenase inhibitor,zileuton,on lung inflammation produced by segmental antigen challenge in human beings..J Allergy Clin Immunol 1996;97:646-654.
28.Denizot Y.Prostaglandin e2 regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells.Biochim Biophys Acta 1999;1450:444-451.
29.Zeidler R,Csanady,M.,Gires,O.,Lang,S.,Schmitt,B.and Wollenberg,B.Tumor cell-derived prostaglandin e2 inhibits monocyte function by interfering with ccr5 and mac-1.FASEB J 2000;14:661-668.
30.Irvin CG Tu,Y.P.,Sheller,J.R.and Funk,C.D.5-lipoxygenase products are necessary for ovalbumininduced airway responsiveness in mice.Am J Physiol 1997;272:L1053-L1058.
31.Robbiani DF,Finch,R.A.,Jager,D.,Muller,W.A.,Sartorelli,A.C.and Randolph,G J..The leukotriene c4 transporter mrpl regulates ccl19(mip-3p,elc)-dependent mobilization of dendritic cells to lymph nodes..Cell(Cambridge,Mass) 2000;103:757-768.
32.Tager AM,Bromley,S.K.and Medoff,B.D.et.al.Leukotriene b4 receptor bltl mediates early effector t cell recruitment..Nat Immunol 2003;4:982-990
33.Hojo M,Suzuki,M.,Maghni,K.,Hamid,Q.,Powell,W.S.and Martin,J.G Role of cysteinyl leukotrienes in cd4+ t cell-driven late allergic airway responses.J Pharmacol Exp Ther 2000;293:410-416.
34.Tohda Y,Nakahara,H.,Kubo,H.,Haraguchi,R.,Fukuoka,M.and Nakajima,S.Effects of ono-1078(pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma..Clin Exp Allergy 1999;29:1532-1536.
35.Underwood DC,Osborn,R.R.,Newsholme,S.J.,Torphy,T.J.and Hay,D.W..Persistent airway eosinophilia after leukotriene(It) d4 administration in the guinea pig:Modulation by the Itd4 receptor antagonist,pranlukast,or an interleukin-5 monoclonal antibody..Am J Respir Crit Care Med 1996;154:850-857
36.Peters-Golden M,Bailie,M.,Marshall,T.et al.Protection from pulmonary fibrosis in leukotrienedeficient mice..Am J Respir Crit Care Med 2002;165:229-235.
37.Bonta ILaP,M.J..Immunomodulatory-antiinflammatory functions of e-type prostaglandins:Minireview with emphasis on macrophage-mediated effects.J Immunopharmacol 1982;4:103-109.
38.Steinbrink K,Paragnik,L,Jonuleit,H.,Tuting,T.,Knop,J.and Enk,A.H.Induction of dendritic cell maturation and modulation of dendritic cellinduced immune responses by prostaglandins..Arch Dermatol Res 2000;292:437-445.
39.Kambayashi T,Wallin,R.P.and Ljunggren,H.G Camp-elevating agents suppress dendritic cell function.J Leukoc Biol 2001;70:903-910.
40.Betz MaF,B.S.(1991) 146,.Prostaglandin e2 inhibits production of th1 lymphokines but not of th2 lymphokines.J Immunol 1991;146:108-113.
41.Peebles J,R.S.,Dworski,R.,Collins,R.D.et al.Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice..Am J Respir CritCare Med 2000;162:676-681.
42.Brach MA,de Vos,S.,Arnold,C,Gruss,H.J.,Mertelsmann,R.and Herrmann,F.Leukotriene b4 transcriptionally activates interleukin-6 expression involving nf-κb and nf-il6..Eur J Immunol 1992;22:2705-2711.
43.Christman JW,Christman,B.W.,Shepherd,V.L.and Rinaldo,J.E.Regulation of alveolar macrophage production of chemoattractants by leukotriene b4 and prostaglandin e2.Am J Respir Cell Mol Biol 1991;5.
44.Dubois CM,Bissonnette,E.and Rola-Pleszczynski,M.Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor Autoregulatory role of leukotriene b4.Am RevRespir Dis 1989;139:1257-1264.
45.Phan SH,McGarry,B.M.,Loeffler,K.M.and Kunkel.S.L..Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites.J Leukoc Biol 1987;42:106-113.
46.Prins BA,Hu,R.M.,Nazario,B.et al..Prostaglandin e2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells.J Biol Chem 1994;269:11938-11944.
47.Rajah R,Nunn,S.E.,Herrick,D.J.,Grunstein,M.M.and Cohen,P.Leukotriene d4 induces mmp-1,which functions as an igfbp protease in human airway smooth muscle cells.Am J Physiol 1996;271:L1014-L1022.
48.Kunkel SL,Spengler,M.,May,M.A.,Spengler,R.,Larrick,J.and Remick,D.Prostaglandin e2 regulates macrophage-derived tumor necrosis factor gene expression..J Biol Chem 1988;263:5380-5384.
49.Ham EA,Soderman,D.D.,Zanetti,M.E.,Dougherty.H.W.,McCauley,E.and Kuehl,Jr,F.A.Inhibition by prostaglandins of leukotriene b4 release from activated neutrophils.Proc Natl Acad Sci USA 1983;80:4349-4353.
50.Standiford TJ,Kunkel,S.L,Rolfe,M.W.,Evanoff,H.L,Allen,R.M.and Strieter,R. M.w.Regulation of human alveolar macrophage-and blood monocytederived interleukin-8 by prostaglandin e2 and dexamethasone..Am J Respir Cell Mol Biol 1992;6:75-81.
51.Shinomiya S,Naraba,H.,Ueno,A.et al.Regulation of tnfa and interleukin-10 production by prostaglandins i2 and e2:Studies with prostaglandin receptor-deficient mice and prostaglandin e-receptor subtype-selective synthetic agonists.Biochem Pharmacol 2001;61:1153-1160.
52.Strassmann G,Patil-Koota,V.,Finkelman,R,Fong,M.and Kambayashi,T..Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin e2..J Exp Med 1994;180:2365-2370.
53.Los M,Schenk,H.,Hexel,K.,Baeuerle,P.A.,Droge,W.and Schulze-Osthoff,K.II-2 gene expression and nf-Kb activation through cd28 requires reactive oxygen production by 5 lipoxygenase.EMBO J 1995;14:3731-3740.
54.Mensing HaC,B.M.Leukotriene b4 induces in vitro fibroblast chemotaxis.J Invest Dermatol 1984;82:9-12.
55.Fireman E,Schwartz,Y.,Mann,A.and Greif,J.Effect of montelukast,a cysteinyl receptor antagonist,on myofibroblasts in interstitial lung disease..J Clin Immunol 2004;24:418-425.
56.Kohyama T,Ertl,R.F.,Valenti,V.et al..Prostaglandin e2 inhibits fibroblast chemotaxis.Am J Physiol 2001;281:L1257-L1263.
57.M.MBaP-G Prostaglandin e(2) inhibits fibroblast migration by e-prostanoid 2 receptor-mediated increase in pten activity.Am J Respir Cell Mol Biol 2005;32:135-141.
58.Goldstein RH,Sakowski,S.,Meeker,D.,Franzblau,C.and Polgar,P..The effect of prostaglandin e2(pge2) on amino acid uptake and protein formation by lung fibroblasts..J Biol Chem 1986;261:8734-8737.
59.Boyle JE,Lindroos,P.M.,Rice,A.B.,Zhang,L.,Zeldin,D.C.and Bonner,J.C.Prostaglandin-e2 counteracts interleukin-1β-stimulated upregulation of platelet-derived growth factor a-receptor on rat pulmonary myofibroblasts..Am J Respir Cell Mol Biol 1999;20:433-440.
60.Kolodsick JE,Peters-Golden M,Larios J,Toews GB,Thannickal VJ,Moore BB.Prostaglandin e2 inhibits fibroblast to myofibroblast transition via e.Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.Am J Respir Cell Mol Biol,2003;29:537-544.
61.Goldstein RHaP,P..The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts.J Biol Chem 1982;257:8630-8633.
62.Baum BJ,Moss,J.,Breul,S.D.,Berg,R.A.and Crystal.R.G.Effect of cyclic amp on the intracellular degradation of newly synthesized collagen..J Biol Chem 1980;255:2843-2847.
63.Clark JG,Kostal KM,Marino BA.Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters.Presence of a factor in lung that increases fibroblast prostaglandin e2 and camp and suppresses fibroblast proliferation and collagen production.J Biol Chem 1982;257:8098-8105.
64.Borok Z,Gillissen A,Buhl R,Hoyt RF,Hubbard RC,Ozaki T,Rennard SI,Crystal RG Augmentation of functional prostaglandin e levels on the respiratory epithelial surface by aerosol administration of prostaglandin e.Am Rev Respir Dis 1991;144:1080-1084.
65.Wilborn J,Crofford LJ,Burdick MD,Kunkel SL,Strieter RM,Peters-Golden M.Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin e2 and to express cyclooxygenase-2.J Clin Invest 1995;95:1861-1868.
66.Vancheri C,Sortino MA,Tomaselli V,Mastruzzo C,Condorelli F,Bellistri G,Pistorio MP,Canonico PL,Crimi N.Different expression of tnf-alpha receptors and prostaglandin e(2)production in normal and fibrotic lung fibroblasts:Potential implications for the evolution of the inflammatory process.Am J Respir Cell Mol Biol 2000;22:628-634.
67.CB K,RG J,NK H,NA H-R,H B,GJ L,SL H,ML F,RJ.M.Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.Am J Pathol 2001;158:1411-1422.
68.Huang S,Wettlaufer SH,C.Hogaboam DMA,Peters-Golden M,February 1 L-L.Prostaglandin e2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via e prostanoid 2 receptor and camp signaling.Am J Physiol Lung Cell Mol Physiol,2007;292:L405-413.
69.R.J.Hodges RGJ,C.P.D.Wheeler-Jones,D.M.Copeman,S.E.Bottoms,G J.Bellingan,C.B.Nanthakumar,G J.Laurent,S.L.Hart,M.L.Foster,et al.Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin e2 production.Am J Pathol 2004;165:1663-1676.
70.Ogushi F,Endo T,Tani K,Asada K,Kawano T,Tada H,Maniwa K,Sone S.Decreased prostaglandin e2 synthesis by lung fibroblasts isolated from rats with bleomycin-induced lung fibrosis.Int J Exp Pathol 1999;80:41-49.
71.Kohyama T,Ertl RF,Valenti V,Spurzem J,Kawamoto M,Nakamura Y,Veys T,Allegra L,Romberger D,Rennard SI.Prostaglandin e(2) inhibits fibroblast chemotaxis.Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-1263.
72.Vibha Lama BBM,Paul Christensen,Galen B.Toews,and Marc Peters-Golden Prostaglandin e2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.Am J Respir Cell Mol Biol 2002;27.
73.Failla M,Genovese T,Mazzon E,Fruciano M,Fagone E,Gili E,Barera A,La Rosa C,Conte E,Crimi N,et al.16,16-dimethyl prostaglandin e2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis.Am J Respir Cell Mol Biol 2008.
74.Charbeneau RP,Christensen PJ,Chrisman CJ,Paine R,3rd,Toews GB,Peters-Golden M,Moore BB.Impaired synthesis of prostaglandin e2 by lung fibroblasts and alveolar epithelial cells from gm-csf-/-mice:Implications for fibroproliferation.Am J Physiol Lung Cell Mol Physiol 2003;284:L1103-1111.
75.Moore BB P-GM,Christensen PJ,Lama V,Kuziel WA,Paine R III,and Toews GB..Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by mcp-1/ccr2 and mediated by pge2..Am J Physiol Lung Cell Mol Physiol 2003;284:L342-L349.
76.M Molina-Molina AS-M,O Bulbena,L Femandez-Zabalegui,D Closa,A Marin-Arguedas,A Torrego,J Mullol,C Picado,and A Xaubet.Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin e2 synthesis.Thorax 2006;61:604-610.
77.Kern Lovgren A JL,Hartney JM,Parsons KK,Audoly LP,FitzGerald GA,Tilley SL,and Koller BH.Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis..Am J Physiol Lung Cell Mol Physiol 2006;291:L144-L156.
78.Koichiro Kamio XL,Hisatoshi Sugiura,Shinsaku Togo,Tetsu Kobayashi,Shinsaku Kawasaki,Xingqi Wang,Lijun Mao,Youngsoo Ahn,Cory Hogaboam,Myron L.Toews,and Stephen I.Rennard Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the camp-pka pathway.Am J Respir Cell Mol Biol 2007;37.
79.Murakami S NN,Itoh T,Kataoka M,lwase T,Horio T,Miyahara Y,Sakai Y,Kangawa K,Kimura H.Prostacyclin agonist with thromboxane synthase inhibitory activity(ono-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.Am J Physiol Lung Cell Mol Physiol 2006;290:L59-65.
80.Ferhana Y.Ali KE,Garret A.FitzGerald,Beatrice Desvergne,Walter Wahli,David Bishop-Bailey,Timothy D.Warner,and Jane A.Mitchell Role of prostacyclin versus peroxisome proliferator-activated receptor receptors in prostacyclin sensing by lung fibroblasts.Am J Respir Cell Mol Biol 2005;34:242-246.
81.Medina L,Perez-Ramos J,Ramirez R,Selman M,Pardo A.Leukotriene c4 upregulates coilagenase expression and synthesis in human lung fibroblasts.Biochim Biophys Acta 1994;1224:168-174.
82.Peters-Golden M,Bailie M,Marshall T,Wilke C,Phan SH,Toews GB,Moore BB.Protection from pulmonary fibrosis in leukotriene-deficient mice.Am J Respir Crit Care Med 2002;165:229-235.
83.Beller TC,Friend DS,Maekawa A,Lam BK,Austen KF,Kanaoka Y.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.Proc Natl Acad Sci U S A 2004;101:3047-3052.
84.Brock TG,Lee YJ,Maydanski E,Marburger TL,Luo M,Paine R,3rd,Peters-Golden M.Nuclear localization of leukotriene a4 hydrolase in type ii alveolar epithelial cells in normal and fibrotic lung.Am J Physiol Lung Cell Mol Physiol 2005;289:L224-232.
85.Izumo T,Kondo M,Nagai A.Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.Life Sci 2007;80:1882-1886.
86.Genovese T,Cuzzocrea S,Di Paola R,Mazzon E,Mastruzzo C,Catalano P,Sortino M,Crimi N,Caputi AP,Thiemermann C,et al.Effect of rosiglitazone and 15-deoxy-delta12,14-prostaglandin j2 on bleomycin-induced lung injury.Eur Respir J 2005;25:225-234.
87.Cruz-Gervis R,Stecenko AA,Dworski R,Lane KB,Loyd JE,Pierson R,King G,Brigham KL.Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis.Respir Res 2002;3:17.